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ABBREVATION INDEX  
A 
ACTB = actin beta 
AD = Alzheimer’s disease 
AIC = Akaike Information Criterion 
AID = APP intracellular domain  
AKT = protein kinase B 
ANOVA = analysis of variance 
Apo = apolipoprotein 
APP = amyloid precursor protein 
Aβ = amyloid beta  
 
B 
BACE = β secretase 
BBB = blood brain barrier 
BMI = body mass index 
BS = blocking solution 
BSA = bovine serum albumin 
 
C 
°C = celsius 
Ca = Calcium 
CERAD = Consortium to Establish a Registry for 
AD 
cDNA = copy DNA 
CO2 = carbon dioxide 
 
D 
DMEM = dulbecco's modified eagle's medium 
DNA = deoxyribonucleic acid 
 
E 
ELISA = enzyme linked immunsorbent assay 
ECL = enhanced chemiluminescence 
 
F 
FAD = familial AD 
 
G 
g = gramm 
GAPDH = glyceraldehyde 3-phosphate 
dehydrogenase 
GSK = glycogen synthase kinase 
 
H 
H2O2 = hydrogen peroxide  
HCL = hydrochlorid acid 
HRP = horse redish peroxidase 
HWE = Hardy Weinberg equilibrium 
 
I 
icv = intracerebroventricular  
IDE = insulin degrading enzyme 
IGF = insulin growth factor 
IL = interleukin 
IR = insulin receptor 
IRS = insulin receptor substrate 
 
K 
KCL = potassium chloride 
kD = kilo Dalton 
 
L 
l = liter 
LOAD = late onset AD 
 
M 
MAO = monoamin oxidase 
ml = millilitre 
mM = millimolar 
 
N 
nAChR =  nicotin actelycholin receptors 
NFT = neurofibrillary tangles 
NINCDS-ADRDA = National Institute of 
Neurological and Communicative Disorders 
and Stroke and the Alzheimer's Disease and 
Related Disorders Association 
nm = nanometer 
NMDAR = glutamate receptors 
NSE = neurospecific enolase 
 
O 
OS = oxidative stress 
 
P 
PCR = polymerase chain reaction 
PI3K = phosphoinositide 3-kinases 
PPAR = peroxisome proliferator-activated 
receptors 
PPIA = peptidylprolyl isomerase A 
PS = presenilin 
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Q 
QRT-PCR = real time reverse transcriptase PCR 
 
R 
RNA = ribonucleic acid 
RPL13A = ribosomal protein L13a 
ROS = reactive oxidative species 
 
S 
sAPPα =soluble N-terminal APP fragment-α 
APP  
SD = standard deviation 
SNP = single nucleotide polymorphism 
STZ = streptozotocin 
 
T 
T1DM = type 1 diabetes mellitus 
T2DM = type 2 diabetes mellitus 
TBS = tris buffered saline 
TDZ = thiazolidinediones 
TNF = tumor necrosis factor  
TOMM = a transporter of proteins across the 
mitochondrial membrane 
 
U 
UTR = untranslated region 
 
V 
VITA = Vienna Transdanube Aging 
 
W 
WB = western blot 
ZUSAMMENFASSUNG 
 
14 
 
ZUSAMMENFASSUNG 
Die neurodegenerative Erkrankung Alzheimer Demenz (AD) ist für etwa 60% der weltweit 35 
Millionen Demenz Patienten ursächlich. Die aktuelle Forschung konzentriert sich hierbei auf 
Assoziationen mit anderen Erkrankungen wie Diabetes Typ 2 (T2DM), potentielle genetische 
Marker, spezifische Signaltransduktionswege im Gehirn und mögliche Modifizierung von 
Proteinen, da weder die Pathogenese noch die Ätiologie von AD vollständig geklärt ist. Im 
Jahr 1999 rückte durch die so genannte "Rotterdam-Studie" eine mögliche Verbindung 
zwischen T2DM und AD in den besonderen Fokus der Wissenschaft, da die Studie darauf 
hinweist, dass T2DM das Risiko eine AD zu entwickeln verdoppeln kann. In der 
Zwischenzeit ist bekannt, dass die Prävalenz an einer AD zu erkranken bei Patienten mit 
T2DM 30% beträgt. Zusätzlich zeigten Medikamente, die häufig zur Behandlung von T2DM 
eingesetzt werden, wie PPARγ (Peroxisom-Proliferator-aktivierte Rezeptoren gamma) 
Agonisten, eine Verbesserung der kognitiven Leistung bei Patienten mit einem frühen 
Stadium der AD. Daher ist es wichtig, nicht nur eine mögliche Verbindung zwischen diesen 
Krankheiten zu untersuchen, sondern auch die Insulin-Signalwege im Gehirn von AD 
Patienten näher zu betrachten. Um dieses komplexe Thema in weiteren Details zu untersuchen 
und zusätzliche Verbindungen zwischen T2DM und AD aufzuzeigen, verwendet die 
vorliegende Studie mehrere biologische Grundlagenmethoden, um die Frage zu klären: "Ist 
ein beeinträchtigter zerebraler Insulin-Signalweg entscheidend für die Entwicklung einer 
AD?"  
Die in dieser Arbeit verwendete Methoden waren i) eine Analyse von Einzel-Nukleotid-Poly-
morphismen (SNP) des Insulin-abbauende Enzym (IDE) Gens in Bezug auf das Risiko eine 
AD und/oder T2DM zu entwickeln; ii) post-mortem histochemische Untersuchungen des 
Gehirngewebes von Patienten mit nur AD, mit AD und T2DM, und mit nur T2DM verglichen 
mit einer altersangepassten Kontrollgruppe; und iii) Untersuchungen neurobiologischer 
Signalwege und Gen-/Protein-Expressions Veränderung einer humanen Neuroblastoma Zell-
linie nach Behandlung mit Amyloid β (Aβ) Peptiden. 
Nach der Analyse der IDE-SNPs in der ausgewählten VITA (Vienna Transdanube Aging) 
Kohorte wurden krankheitsspezifische Effekte entdeckt. Der Upstream-Polymorphismus 
(IDE2) minderte das Risiko an einer AD zu erkranken, während der downstream gelegene 
Polymorphismus (IDE7) das Risiko T2DM zu bekommen, erhöhte. Basierend auf den SNP 
Ergebnissen, beschreibt die vorliegende Studie ein Modell, das Variationen innerhalb des IDE 
Promotors und/oder in untranslatierten Regionen unterschiedliche Auswirkungen auf die IDE 
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Expression haben können und somit potentiell Auswirkungen auf die Entwicklung von AD 
und T2DM haben können.  
Darüber hinaus konnte die menschliche post-mortem Studie zeigen, dass sowohl AD als auch 
T2DM Patienten eine signifikant geringere Dichte der Insulin-Rezeptoren (IR) im Hippo-
kampus hatten, während eine signifikant erhöhte Dichte von inaktiven phosphorylierten 
PPARγ bei allen Patientengruppen detektiert werden konnte. Die vorliegende post-mortem 
Studie konnte zwar gemeinsame histologische Merkmale von AD und T2DM aufzeigen, 
jedoch keine direkte Verbindung der beiden Erkrankungen nachweisen.  
Obwohl AD heutzutage nicht mehr nur noch durch die Amyloid-haltigen Plaqueablagerungen 
und durch die hyperphosphorylierten Tau Proteine gekennzeichnet ist, spielt das übermäßige 
Vorhandensein von Aβ42 in den Gehirnregionen von AD Patienten eine entscheidende 
Schlüsselrolle. Bis dato ist es immer noch nicht vollständig geklärt, welche physikalische 
Form von Aß42 verantwortlich für eine Entwicklung von AD ist. Die vorliegende Arbeit 
untersuchte, welche Auswirkungen die Aggregatszustände von Aß42 auf Gene und Proteine 
des Insulin-Signalweges und auf die Amyloid-Kaskade haben. Es konnte gezeigt werden, dass 
die oligomere Variante von Aß42 speziell die Gen- und Proteinexpression von Glykogen-
Synthase Kinase (GSK) 3β als auch ihre Enzymaktivität deutlich erhöht hatte, jedoch im 
Gegenzug die IR Gen- und Proteinexpression stark gehemmt hatte. Zusätzlich wurde die 
Wirkung von Aß42 auf die Monoamin Oxidase-B (MAO-B) untersucht. Es wurde ein Effekt 
beider untersuchten aggregierten Formen von Aß42 auf die Enzymaktivität entdeckt. Jedoch 
führte hier die fibrilläre Variante zu einer deutlich erhöhten Aktivität von MAO-B, während 
die oligomere Variante die Enzymaktivität inhibiert. Frühere Studien konnten bereits eine 
Beteiligung von erhöhter MAO-B-Aktivität in AD nachweisen, aber die vorliegende Arbeit 
zeigt erstmals eine direkte Verbindung zwischen den Aggregatzuständen von Aß42 auf die 
Enzymaktivität auf.  
Abschließend können die Ergebnisse der vorliegenden Arbeit zu folgenden Schluss-
folgerungen zusammengefasst werden: 
Obwohl AD und T2DM bis zu einem gewissen Grad gemeinsame Merkmale aufzeigen, fehlt 
es an einer direkten Verbindung, und somit sollten die Krankheiten weiterhin eher unabhängig 
als miteinander verbunden betrachtet werden. Jedoch scheint die Beeinträchtigung des 
zerebralen Insulin Signalweges ein weiteres gefestigtes Merkmal von AD zu sein. 
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SUMMARY  
The neurodegenerative disorder Alzheimer's disease (AD) is the cause of approximately 60% 
of the world's 35 million patients suffering from dementia. Current research focuses here are 
on association with other diseases such as diabetes type 2 (T2DM), possible genetic markers, 
specific signal transduction pathways within the brain and potential protein modification, 
because the pathogenesis and etiology of AD are still not fully understood. Specifically 
association of T2DM with AD came to the focus with the so-called "Rotterdam study" in 
1999, indicating that T2DM doubles the risk of developing AD. In the meantime, it is known 
that the prevalence rate in patients with T2DM is 30%. Drugs commonly used in the treatment 
of T2DM such as peroxisome proliferator-activated receptors gamma (PPARγ) agonists show 
improvement of the cognitive abilities in patients with early stage of dementia, with potential 
therapeutically relevance. Therefore it is important not only to investigate a link between 
these diseases, but also to investigate the insulin signaling pathway in the brain of AD 
patients. In order to investigate this complex issue in more details and demonstrate additional 
links between T2DM and AD, the present study used several basic biological methods to 
clarify the question: "Is impaired insulin signaling pathway within the brain crucial for the 
development of AD?" from several points of view. The methods used in this work have been 
i) an analysis of single nucleotide (SNP) polymorphism of the insulin-degrading enzyme gene 
(IDE) in relation to risk of AD and / or of T2DM, ii) post-mortem histochemical studies of 
brain tissue of patients with only AD, with AD combined with T2DM and with only T2DM 
compared with an age-matched control group, and iii.) investigations of neurochemical 
pathways and gene/protein expression changes of a human cell culture as a consequences of 
amyloid β (Aβ) treatment. 
After analysis of the IDE SNP polymorphism in the selected VITA (Vienna Trans Danube 
Aging) cohort disease-specific effects were discovered. The upstream polymorphism (IDE2) 
was found to influence AD risk in a protective manner, while the downstream polymorphism 
(IDE7) modified the T2DM risk. Based on the SNP results, the presented study delineate the 
model that IDE promoter and 3‟ untranslated region/downstream variation can have different 
effects on IDE expression, maybe a relevant endophenotype with disorder-specific effects on 
AD and T2DM susceptibility.  
Furthermore, the human post-mortem studies could show that both AD as well as T2DM 
patients had a significantly lower density of the insulin receptor (IR) in the hippocampus, 
whereas a significantly increased density of inactive phosphorylated PPARγ has been found 
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and this persisted even in patients with both diseases. Summarizing the histological study, it 
was possible to reveal common histological features of AD and T2DM, but no direct 
connection between the two diseases. 
Although AD is nowadays not only characterized by amyloid-containing plaque deposits and 
by the hyperphosphorylation of tau protein, the excessive Aβ42 presence in the brains of AD 
patients is still playing a key role. Up to date it is still not entirely clear which physical form 
of Aβ42 is responsible for the development of AD. The present work investigated, what impact 
has the state of aggregation of Aβ42 on genes and proteins of the insulin signaling pathway 
and the amyloid cascade. It could be shown that the oligomeric variant enhanced specifically 
the gene and protein expression of glycogen synthase kinase (GSK) 3β and also the enzyme 
activity was significantly increased, but has in turn strongly inhibited the IR gene and protein 
expression. Additionally, the effect of Aβ42 on monoamine oxidase B (MAO-B) was 
examined. An effect of both aggregated forms of Aβ42 had on enzyme activity was discovered. 
However, the fibrillar variants led to significantly increased activity of MAO-B while the 
oligomeric variants inhibited the enzyme activity. Several previous studies have demonstrated 
the involvement of increased MAO-B activity in AD, but the present work provides for the 
first time a direct link between the states of aggregation of Aβ42 to enzyme activity.  
Finally the results of the presented thesis can be summarized to following conclusion:  
Although AD and T2DM sharing some degrees of common features, still there is a lack of 
direct association, and therefore the diseases must be considered more independent rather than 
linked. But the impaired cerebral insulin signaling pathway seems to be another manifested 
hallmark of AD. 
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INTRODUCTION 
GENERAL INTRODUCTION 
Alois Alzheimer (*14th of June, 1864; † 19th of December, 1915) described already 1906 in 
Tübingen the first symptoms of the progressive neurode-generative disorder “Alzheimer’s 
disease (AD)” according to his observations of his patient Auguste Deter 1. The patient 
showed progressive loss of memory, deteriorating orientation in time and space, became 
bedridden and incontinent, and died four and half year after the first symptoms. At post-
mortem examination, Alois Alzheimer noted the presence of abnormal fibrous inclusions 
within the perikaryal cytoplasm of pyramidal neurons and neuritic plaques with a central core 
of amyloid-β (Aβ) peptides. Up to date neuropathological diagnosis of AD is based on the 
frequency of neuritic plaques in neocortex determined according to the Consortium to 
Establish a Registry for AD (CERAD) criteria 2 (table 1) while the Braak scores 3 define the 
distribution of neurofibrillary tangle (NFT) ,which are composed of hyperphosphorylated 
forms of the microtubule-associated protein tau, pathology in the entorhinal cortex, 
hippocampus, and neocortex (figure 1). 
  
Table 1: Age related plaque score according to the Consortium to Establish a Registry for Alzheimer’s 
disease 
Age of patient at 
death (years) 
Frequency of plaques 
none sparse moderate frequent 
<50 0 C C C 
50-75 0 B C C 
>75 0 A B C 
 
An age related plaque score is determined using patientʼs age along with plaque frequency in the most heavily 
affected brain section like frontal, temporal and/or parietal cortex. 0= No histologic evidence of Alzheimer’s 
disease (AD); A= Histologic findings are uncertain evidence of AD; B= Histologic findings suggest the 
diagnosis of AD; C= Histologic findings indicate the diagnosis of AD 2 
 
The progressive deposition of NFT has been divided into six stages and AD is usually 
diagnosed when the neuropathological changes have reached stage III to VI. In the 
transentorhinal stage (Braak stages I and II), the deposition is still restricted to the entorhinal 
cortex and the parahippocampal cortex, which play a role in the formation of memories and 
the identification of odors Disturbed function in these areas probably underlies early clinical 
changes of AD, including delayed memory recall and odor identification 4, that disrupts daily 
life, challenges in planning or solving problems, difficulty completing familiar tasks at home, 
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at work, or at leisure, confusion in time or place, trouble understanding visual images and 
spatial relationships, new problems with words in speaking or writing, misplacing things and 
losing the ability to retrace steps, decreased or poor judgment, withdrawal from work or social 
activities, changes in mood and personality (reviewed in 5). Although memory impairment is 
the earliest cognitive change in AD, distinguishing early disease from normal aging can be 
difficult. With disease progression, signs and symptoms include confusion, irritability, and 
aggression, mood swings, language breakdown, loss of long-term memory, and general 
withdrawal decline. The mean life expectancy following diagnosis is approximately 7 years 6. 
 
 
 
 
. 
 
 
 
 
 
 
 
 
Figure 1: Braak stages define the distribution of neurofibrillary tangle (NFT) pathology in brains of 
Alzheimer’s disease patients. At Braak stage I, the NFT have begun to form in the transitional entorhinal 
region; at Braak stage II, NFT are causing cell death (yellow) in the transitional entorhinal region and 
aggregating in the hippocampus (pink) and in the cortex (blue). In stages III and IV (limbic stages), the NFT are 
already in the hippocampal formation and in other centers of the limbic system before. Braak stages V and VI 
(isocorticale stages) are the final stages of AD, where the presence of NFT already in the isocortex. Images 
according to 3 
 
 
EARLY AND LATE ONSET OF ALZHEIMER`S DISEASE 
Two types of AD are needed to be distinguished: early onset AD, also called familial AD 
(FAD) is mostly genetically based, while the late onset AD (LOAD) is a sporadic form and 
probably involved both polygenetic and environmental factors. FAD accounts for 
approximately 5% of all AD cases and leads to an earlier begin of the disease with around 45 
years of age. Genes involved in FAD are coding for amyloid precursor protein (APP), 
presenilin 1 (PS1) and presenilin 2 (PS2). Mutations in the PS1 and PS2 genes account for as 
much as 50% of all FAD cases. More than 30 mutations in the APP gene and more than 180 
Figure 
1:Braak 
stages 
define the 
distribution 
of 
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mutations in PS1 and PS2 genes have been already identified. Mutations in all three genes 
were shown to increase the production and aggregation of Aβ (reviewed in 7). Testing of 
asymptomatic adults who are at risk for FAD caused by mutations in the APP, PS1 or PS2 
genes is available clinically. However, genetic testing results for at-risk asymptomatic adults 
can only be interpreted after the disease-causing mutation has first been identified in the 
affected family member. It should be emphasized that testing of asymptomatic at-risk 
individuals with nonspecific or equivocal symptoms is predictive but is not diagnostic. In 
addition, obtaining results from genetic testing can affect an individual‟s personal 
relationships as well as their emotional well-being, and it may even cause depression
8
. 
Clinically and histopathologically, FAD cannot be discriminated from LOAD. The majority 
of AD patients (~ 95%) have LOAD and the disease usually develops after 65 years of age. 
Expression of the apolipoprotein E allele ε4 (ApoEε4) is one of the risk factors identified for 
LOAD and this risk is highest for individuals that carry two ApoEε4 alleles (ε4/ε4 genotypes). 
The ε4/ε4 genotype is uncommon, occurring in about 1% of normal Caucasian controls. In 
contrast, the ε4/ε4 genotype occurs in nearly 19% of LOAD populations. Women with an 
ApoEε4/ε4 genotype have a 45% probability of developing AD by the age of 73, whereas men 
have a 25% risk of developing AD by that age. AD risk is also lower for individuals with only 
one ApoEε4 allele (by age 87) or no ApoEε4 allele (by age 95) (reviewed in 9). The role of 
ApoEε4 in LOAD pathogenesis is not fully elucidated, but it has been suggested that ApoEε4 
is important in trafficking of Aβ peptide. Recently discovered proteins encoded by risk genes 
of LOAD are apolipoprotein J (clusterin, an Aβ peptide chaperone), TOMM40 (a transporter 
of proteins across the mitochondrial membrane) and a sortilin-related receptor, which 
functions to partition APP away from β-secretase and γ-secretase, which are the main 
cleavage enzymes of APP 
10
. Additional factors, such as hypertension, diabetes mellitus, 
hyperlipidemia, hyperhomocysteinemia, coronary and peripheral artery diseases, alcohol, 
smoking, obesity, levels of physical or mental activity, levels of education, and environmental 
exposures have been investigated to identify risk factors for LOAD (reviewed in 
11
). The main 
focus of this on hand dissertation based on several published manuscripts lay on LOAD and 
so the following chapters are concentrating especially on this form of AD. 
 
AMYLOID β CASCADE HYPOTHESIS 
As mentioned before the hallmarks of AD are NFTs and accumulation deposits of Aβ 
peptides, but the latter being the focus of this thesis. The Aβ cascade hypothesis affirms some 
INTRODUCTION 
 
21 
 
major abnormality of processing of the APP that causes an overproduction of the Aβ42 
fragment with a molecular weight of 4kDa. APP is a transmembrane protein expressed in 
several different tissues but is mainly concentrated in synapses of neurons. The physiologic 
function of APP remains undefined, but immunohistochemical studies have localized APP 
activity to the plasma membrane, the trans-Golgi network, the endoplasmic reticulum, and the 
endosomal, lysosomal, and mitochondrial membranes 
12
 and it has been implicated as a 
regulator of synapse formation, neural plasticity 
13
 and iron export 
14
. It can be processed 
through the so called “amyloidogenic” or the “non-amyloidogenic” pathway. In this process, 
three enzyme complexes are involved; α-, β- and γ-secretase. The non-amyloidogenic 
pathway cleaves APP through α- and γ- secretases and results in a p3 peptide, in a soluble N-
terminal APP fragment-α (sAPPα) and in an APP intracellular domain (AID). It is suspected 
that sAPPα has a neuroprotective function 15, AID seems to regulate phosphoinositide-
mediated calcium signaling pathway 
16
, and the function of p3 remains unclear. The 
amyloidogenic pathway is the cleavage of APP by β-secretase (BACE) instead of α-secretase, 
and produces the Aβ peptides, but also sAPPβ and AID. There are several possible lengths of 
Aβ peptides, since the C-terminus of the γ-secretase can cut at different positions. The length 
of these Aβ peptides can vary between 39-42 amino acids, wherein the Aβ40 peptides are 
soluble and the Aβ42, are insoluble and can accumulate. Because of its role in Aβ production, 
BACE is a possible target for potentially new drugs inhibiting Aβ peptides production 17. 
However, the mechanisms that contribute to especially abnormal Aβ42 accumulation of AD 
are not fully understood, both increased production and decreased degradation have been 
observed 
18
. At present, it is not understood whether these peptides act via receptors or 
whether membrane binding alone leads to synaptic and neuronal degeneration. Membrane 
interaction of Aβ42 peptides could occur via hydrophobic carboxy-terminal domain or by 
electrostatic interactions mediated by the charged amino acids in the amino-terminal domain. 
Aβ42 may bind to the cell membrane to form channels or pores that disrupt ion homeostasis, 
hence leading to neuronal dysfunction (reviewed in 
19
). It is know that it can bind to nicotin 
acetylcholine receptors (nAChR), glutamate receptors (NMDAR) and calcium (Ca)
2+
 ion 
channels (e.g. voltage-dependent calcium channels, transient receptor potential cation 
channels) and causes Ca
2+
 influx and elevates the levels of potentially toxic reactive oxygen 
species (ROS) in an NMDAR-dependent manner. Several reports of the effect of Aβ42 on 
nAChRs are conflicting. Some studies have reported that Aβ42 activates nAChRs, while others 
indicate that Aβ42 inhibits nAChRs. For example, physiological levels of Aβ42 can activate 
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while toxic levels inhibit presynaptic nAChR and evoke changes in presynaptic Ca
2+
 levels in 
rat hippocampus and neocortex. Immunohistochemical studies on human sporadic AD brains 
show that Aβ42 and nAChR, are both present in neuritic plaques and co-localize in individual 
cortical neurons suggesting that Aβ42 could be tightly associated with nAChR (reviewed  
in 
20
). Loss of synaptic terminals or neuronal degeneration could cause the associated decline 
in cognitive functions that characterizes AD. Whether the neurotoxic and synaptotoxic actions 
of Aβ42 are separate activities or whether they share common mechanisms is not known. 
 
NEUROTOXICITY OF DIFFERENT AMYLOID β SPECIES 
Aβ42 are able to adopt many differently shaped aggregates including amyloid fibrils 
21
 as well 
as nonfibrillar aggregates that are also termed Aβ42 “oligomers” 
22
 (figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is not well established which Aβ42 state is most responsible for AD or why. Recent evi-
dence strongly implicates Aβ42 oligomers as the proximal pathogenic trigger 
23
. These 
oligomers are markedly elevated in the brain and cerebrospinal fluid of post-mortem AD 
patients and appear to play a critical role in the synaptic failure and memory deficits of early 
AD 
24. The importance of Aβ42 oligomers is especially evident as they appear necessary and 
sufficient to alter long term potential in vivo 
25
 and in vitro 
26
 and as they appear to actually 
Figure 
2:Electro
n 
microsco
pe 
pictures 
of 
soluble 
and 
Figure 2: Electron microscope pictures of soluble and aggregated Aβ42 peptides. 5µl of samples were 
spotted on a glow discharged, carbon-coated grid and incubated for 5 min, washed with distilled water, fixed 
with 2.5% glutaraldehyde, stained with a 1% (w/v) aqueous uranyl acetate solution, and examined using a 
transmission electron microscope. 20.000 fold magnification. A. black arrow points to soluble Aβ42 peptides; 
B. white arrow points to aggregated Aβ42 peptides (own images; for details see Manuscript III). 
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reduce the density of synapses 
27
. At the molecular level, different Aβ42 aggregates act by 
increasing inward excitatory post-synaptic currents with membrane depolarization through the 
AMPA and NMDA channels 
28
, and they are also able to alter neuronal architecture 
29
, cause 
perturbations in axonal transport and even down-regulate cell surface levels of NMDA 
receptors 
30
. Aβ42 is able to bind to a variety of biomolecules, including lipids, proteins and 
proteoglycans, like integrins, or APP itself 
31. The binding of Aβ42 to membrane lipids 
facilitates Aβ42 aggregation, which in turn disturbs the structure and function of the 
membranes, such as membrane fluidity or the formation of ion channels and can 
hypothetically sparking a signal that leads to cell death or acting via intracellular initiated 
damage, e.g., death through a calcium mediated mechanism 
32
, or disturbing physiological ion 
exchange 
33
. One of the most known and studied effects of Aβ42 is, in fact, its ability to 
induce, and be induced by, oxidative stress (OS). In 2004, Riederer et al. already reviewed the 
link between OS and AD, especially regarding the increased monoamine oxidase B (MAO-B) 
activity 
34
. MAO-B is a flavin containing enzyme localized in the outer mitochondrial 
membrane and is responsible for the oxidative deamination of neurotransmitters 
(norepinephrine, dopamine and serotonin) and exogenous amines. During its catalytic activity 
it produces hydrogen peroxide formed in the reaction, which is a possible source for oxidative 
stress, and inhibition of MAO-B has a neuroprotective effects for AD. Not only increased 
MAO-B activity is associated with AD, also other oxidative damage of biomacromolecules 
has been already described in the brains of AD patients: i.) DNA and RNA oxidation is 
marked by increased levels of 8-hydroxy-2-deoxyguanosine and 8-hydroxyguanosine; ii.) 
protein oxidation is marked by elevated levels of protein carbonyl and nitration of tyrosine 
residues, iii.) lipid peroxidation is marked by high levels of thiobarbituric acid-reactive 
substances, malondialdehyde, 4-hydroxy-2-nonenal, and isoprostanes and altered 
phospholipid composition; and iv.) modification to sugars is marked by increased glycation 
and glycoxidation (reviewed in 
35
). Both amyloid deposits and soluble Aβ42 seem to drive the 
accumulation of reactive oxidative species (ROS) 
36
. Furthermore, Aβ42 can strike the 
production of pro-inflammatory molecules, such as TNF-α and IL-1β, leading to microglial 
activation, production of an immune response, and to an enhanced production of APP and its 
processing to generate more Aβ42 (reviewed in 
37
). Additionally Aβ42 oligomers interact with 
neuronal insulin receptor (IR) via binding to cause impairments of the receptor expression and 
function 
38,39
. Normally, activation of IR leads to the phosphorylation of phosphoinositide-3 
kinase (PI3K), which leads to an activation of AKT. PI3K has been identified as second 
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messenger system providing anti-apoptotic signal to various cell types 
40
 and also 
neuroprotection against extracellular Aβ42 toxicity is dependent on PI3K pathway 
41,42
. Once 
AKT is activated, it leads to the phosphorylation and consequently to the inactivation of 
glycogen synthase kinase (GSK) 3 
43
 (figure 3):  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Insulin signalling pathway. Insulin activates the transmembran insulin receptor (IR) leading to the 
activation of intracellular insulin receptor substrate (IRS). Active IRS leads to phosphorylation of 
phosphoinositide-3 kinase (PI3K), which activates protein kinase B (AKT). Active AKT leads to the 
phosphorylation and consequently to the inactivation of glycogen synthase kinase (GSK) 3α and 3. P = 
phosphorylated.   →   = activation;    •   = inhibition 
 
 
There are two GSK3 genes from which GSK3α and GSK3β are derived. GSK3α and GSK3β 
are ubiquitously expressed, constitutively active, proline-directed serine/threonine kinases 
involved in a variety of cellular processes including glycogen metabolism 
44
, gene 
transcription 
45
, apoptosis 
46
 and microtubule stability 
47
. As seen in figure 3 GSK3 can be 
modulated by insulin and over-activity of GSK3 accounts for memory impairment, tau 
hyperphosphorylation, increased A production and local plaque-associated microglial-
mediated inflammatory responses; all of which are hallmark characteristics of AD (reviewed 
in 
48
). Thus, although normal insulin and IR activity help to defend against the accumulation 
of toxic Aβ42 oligomers, the IR themselves are vulnerable to oligomer-initiated dysfunction. 
Another interesting factor is, that the insulin degrading enzyme (IDE) apart from its primary 
target insulin, additionally degrades Aβ40, Aβ42 and the AID and to eliminate A42 neurotoxic 
P 
Figure 3:Insulin 
signalling 
pathway. 
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effects 
49
. The first evidence that IDE might be involved in A42 degradation was found by 
Kurochkin and Goto in 1994, who demonstrated that purified rat IDE efficiently degrades 
synthetic A42 in vitro 
50
. Subsequently, it was shown that an IDE-like activity from soluble 
and synaptic membrane fractions of human post-mortem tissue both degrade Aβ42 peptides 
51,52; moreover, IDE doesn‟t distinguish between endogenous and synthetic Aβ42 as substrate 
in vitro 
53,54. The link between Aβ42, IR and IDE leads to the question: “Is an impairment of 
the insulin signalling pathway a potential trigger for AD?” 
 
ALZHEIMER’S DISEASE=TYPE 3 DIABETES? 
The association between type 2 diabetes mellitus (T2DM) and increased risk of dementia in 
the elderly is well investigated 
55,56
 and it started all with the groundbreaking “Rotterdam 
study” in the year 1999 57. They recruited 6,370 elderly subjects and studied them for around 
2 years. 126 developed dementia and 89 of these were specifically diagnosed with AD. They 
detected that T2DM doubled the risk of a patient having dementia and patients on insulin had 
four times the risk. Starting from this study, multiple possible mechanisms for this association 
have been proposed, including the direct effects of hyperglycaemia, insulin resistance, and 
insulin-induced amyloid-peptide amyloidosis in the brain 
58
. In the early stages of AD, ce-
rebral glucose utilization is reduced by as much as 45%, and blood flow by ∼18% 59,60 and 
since it is known that insulin is also synthesised in the central nervous system, it may 
contribute to an underlying pathophysiological mechanism for AD. Insulin binds to IRs in the 
brain, most of which are located in the cerebral cortex, olfactory bulb, hippocampus, 
cerebellum, and hypothalamus and activates not only signaling pathways associated with 
learning and long-term memory; it also helps to regulate processes such as neuronal survival, 
energy metabolism, and plasticity. These processes are required for learning and memory. In 
addition to regulating blood sugar levels, insulin functions as a growth factor for all cells, 
including neurons in the brain. Thus, insulin resistance or lack of insulin, in addition to 
adversely affecting blood sugar levels, contributes to degenerative processes in the brain 
(reviewed in 
61
). Peripheral insulin resistance, therefore, affects cognition. Furthermore the 
fact that insulin is a common substrate for most of the identified Aβ-degrading enzymes, such 
as IDE, has drawn attention of investigators to roles of insulin signaling in Aβ clearance. 
Increases in insulin levels frequently seen in insulin resistance may compete for these 
enzymes and thus contribute to Aβ accumulation 62. The fact that extracellular A42 
deposition is one of the hallmarks of AD made IDE a promising candidate gene involved in 
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disease susceptibility. Several studies associated linkage-peaks over the IDE region with 
LOAD 
63
, age of onset in familial AD 
64
 and high plasma Aβ42 levels 
65
. A recent study found 
that variants in the proximal IDE promoter increase transcription and thus provide a possible 
mechanism explaining the protective effect on AD susceptibility found for the examined 
polymorphisms 
66
. Furthermore, validated linkage peaks with the metabolic syndrome T2DM 
were found in the same region 
67-70
.  Not only enzymes are involved of the cleavage of Aβ. 
Circulating insulin like growth factor 1 (IGF-1) has been reported to play a role in Aβ 
clearance probably via facilitating brain-blood barrier (BBB) transportation 
71
. Additionally in 
the endothelium of the BBB and glial cells, insulin signaling is reported to regulate protein-
protein interactions in an uptake cascade involving low density lipoprotein receptor-related 
protein and its ligands ApoE and α2-macroglobulin, a system known to bind and clear Aβ via 
endocytosis and/or vascular transport 
72
. 
A summary of some of the earlier findings in AD, including the impaired glucose utilization, 
OS via mitochondrial dysfunction, reduced ATP production, and energy shortage, led to the 
hypothesis that these abnormalities were mediated by desensitization of the neuronal IR. 
Hoyer and colleagues were among the first to suggest that reduced levels of brain insulin may 
precipitate a cascade resulting in disturbances in cellular glucose, acetylcholine, cholesterol, 
and ATP levels, impaired membrane function, accumulation of amyloidogenic derivatives, 
and hyper-phosphorylation of tau, i.e. that AD may represent a brain form of T2DM 
73,74
. The 
question: “Can AD be described as a kind of type 3 diabetes?” was coined in 2005 by 
Suzanne de la Monte and her team 
75
. They analyzed 45 post-mortem brains of patients of 
varying Braak stages of AD neurodegeneration and found that insulin expression was 
inversely proportional to the Braak stage with an 80% decrease in the number of insulin 
receptors in AD patients compared to normal subjects with the ability of insulin to bind to the 
receptors was compromised. The expression of insulin, IGF-1 and -2 and their receptors 
mRNA was reduced. The team termed it type 3 diabetes because it includes elements of both 
types 1 and 2 diabetes, as there is both a decrease in the production of insulin and a resistance 
to IRs. The post-mortem studies inspired a rat model in which intracerebroventricular (icv) 
injection of streptozotocin (STZ) were conducted. STZ is a nitrosamide methylnitrosourea 
linked to D-glucose, and is a drug selectively toxic for insulin producing/secreting cells, as 
following systemically application. STZ enters the cells via the glucose transporter 2 
(GLUT2), mainly localized in pancreatic b-cells (to a certain extent also in hepatocytes and 
absorptive epithelial cells of the intestine and kidney). Once STZ is metabolized, the N-
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nitrosoureido is liberated and caused DNA damage and cell death through generation of ROS 
76
. STZ icv did not cause a systemic diabetes mellitus 
77,78
 and is normally used in lower 
dosages than used for systematic application, but impairs brain glucose utilization oxidative 
metabolism, IR function, and spatial learning and memory. Moreover, icv-STZ treatments 
produced long-term and progressive deficits in learning, memory, cognition, behavior, and 
cerebral energy balance. Therefore, the icv-STZ model recapitulates many characteristic 
features of AD, like long-term and progressive deficits in learning, memory, cognition, 
behavior, cerebral energy balance and demonstrates a cause-effect relationship between 
insulin deficiency and resistance and AD-type neurodegeneration, like a Type 3 diabetes 
(reviewed in 
79
). Figure 4 demonstrates a possible pathway of insulin, insulin resistance, OS, 
Aβ and T2DM involved in AD modified according to de la Monte (2012) 80: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Brain insulin resistance and amyloid beta (Aβ)-mediated neurotoxicity. Brain insulin resistance 
caused by peripheral insulin resistance diseases or intrinsic/genetic processes, toxic exposures or environmental 
factors contributing to neurodegeneration promote neuroinflammation and increased expression of amyloid 
precursore protein (APP). Through the action of β and γ secretases, APP is cleaved to generate 40–42 kD Aβ 
peptides that aggregate and form insoluble fibrils and plaques, or oligomers. Aβ oligomers promote oxidative 
stress and activate kinases that lead to tau accumulation, hyperphosphorylation and eventual ubiquitination, 
misfolding and aggregation. Aβ can block insulin-receptor function and contribute to insulin resistance. Carriers 
of the apoliprotein Ee4 allele or presenilin mutations are predisposed to abnormal APP cleavage, and Aβ 
accumulation, aggregation and fibril formation, correlating with increased rates and familial occurrences of 
Alzheimer‟s disease. This scenario depicts a positive feedback or reverberating loop linking Aβ and oligomer 
accumulation/toxicity with brain insulin resistance, and vice versa. GSK3β = glycogen synthase kinase 3β; OS= 
oxidative Stress; PI3K= phosphoinositide-3-kinase; ↓ indicates decrease; ↑indicates increase. Modified 
according to 
80
 
Figure 4: Brain insulin resistance and amyloid precursor protein (APP) Aβ-mediated 
neurotoxicity.  
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Role of peroxisome proliferator-activated receptor γ 
The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is a newly 
recognized potential therapeutic target for the treatment of AD. It is a member of a family of 
three (α/γ/δ) related nuclear receptors that act as whole body lipid sensors and each member 
functions to regulate a unique subset of genes responsible for lipid and energy metabolism 
81
. 
The natural ligands of PPARγ include long-chain fatty acids, eicosanoids, oxidized 
lipoproteins and lipids, corresponding well to its function in regulating the metabolic response 
to dietary lipid intake.
 
Thus, PPARγ has been targeted for drug development for the treatment 
of T2DM. Two thiazolidinedione (TZD) agonists of PPARγ, Actos™, (pioglitazone) and 
Avandia™ (rosiglitazone) are widely prescribed for this disease 82. TDZ act as insulin 
sensitizers and reduce glucose, fatty acid, and insulin blood concentrations. 2005 Watson et 
al.
 83
 have reported the results of a small clinical study examining the effects of rosiglitazone 
in patients with mild AD. They found that 6 months of drug treatment resulted in enhanced 
memory and cognitive function compared to placebo-treated control patients. Afterwards the 
results of a phase II clinical trial, enrolling over 500 patients with mild to moderate AD were 
reported. These patients were treated with rosiglitazone (or placebo) for 6 months. Patients 
receiving rosiglitazone were found to have enhanced attention and memory, compared to 
those receiving placebo. Importantly, patients possessing an ApoEε allele did not respond to 
the therapy. A large phase III trial of rosiglitazone in AD patients is currently underway 
(reviewed in 
82). A possible mechanism of PPARγ agonist action comes from the fact that a 
consensus binding site for PPARγ was found in the BACE promoter. PPARγ activation by 
agonists such as TZD results in a decrease of BACE transcription, expression and activity 
84
. 
Furthermore, lack of PPARγ led to an increase of BACE promoter activity 85, which suggested 
that PPARγ could be a repressor of BACE. PPARγ levels are decreased in AD brain, 
indicating that inflammatory events may decrease PPARγ transcription. Furthermore, in vitro 
experiments have shown that inflammatory cytokines and oxidative stress decrease PPARγ 
levels. Therefore, these findings suggest the existence of a down-regulation of PPARγ under 
inflammatory conditions, which would result in an increase in BACE transcription and Aβ 
generation 
86
. Furthermore dʼAbramo et al.87 could indicate that PPARγ decreases the cellular 
content of APP without affecting its mRNA level, thus implying a post-transcriptional event, 
unlikely to be linked to the inhibition of the secretase pathways. Importantly, the evidence 
that PPARγ stimulates the ubiquitination of APP supports the fact that the Aβ-lowering effect 
of PPARγ is due to the proteasome-mediated degradation of APP. Additionally they could 
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show that PPARγ, by decreasing Aβ secretion, protects the cells against hydrogen peroxide 
(H2O2)-mediated necrosis. Thus, it seems that PPARγ agonist can represents new therapeutic 
target in treating AD. 
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THESIS OUTLINE 
AIMS AND QUESTIONS 
The possible association between T2DM and increased risk of AD in the elderly is in focus of 
the update AD research. Multiple possible mechanisms for this association have been 
proposed, including direct effects of hyperglycaemia, insulin resistance, and insulin-induced 
Aβ amyloidosis in the brain. Those observations are not without controversy, and a 
longitudinal survey revealed that although marginal diabetics had a significantly increased 
risk for future development of full diabetes, dementia, or AD, the risk effects were 
independent rather than linked. Thus, further investigations are necessary to delineate possible 
links.  
Aim of this thesis was to use several molecular biological methods including analysis of SNP 
polymorphism, immunohistochemistry of post-mortem brain tissue as well as human cell 
culture model for investigations of biological pathways to ascertain this complex issue from 
several sides in order to get a more profound knowledge about basic principles underlying 
AD. The following main questions were addressed: 
 
1. Do variations in the IDE gene, which is encoded for a cleavage enzyme for insulin and 
Aβ42, have an impact on AD and/or T2DM susceptibility? (the corresponding results 
are summarized in Manuscript I, see below) 
 
2. Which common histopatholigical features are sharing patient with solely AD, AD 
combined with T2DM, solely T2DM and is there a missing link? (the corresponding 
results are summarized in Manuscript II, see below) 
 
3. Which influence does the aggregation form of Aβ42 peptides have on gene expression, 
protein expression and enzyme activity involved in insulin and APP pathways? (the 
corresponding results are summarized in Manuscript III, see below) 
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OVERVIEW OF MANUSCRIPTS 
ABSTRACT MANUSCRIPT I 
 
Disorder-specific effects of polymorphisms at opposing ends of the Insulin 
Degrading Enzyme gene. 
 
Jasmin Bartl, Claus-Jürgen Scholz, Margareta Hinterberger, Susanne Jungwirth, Ildiko 
Wichart, Michael K Rainer, Susanne Kneitz, Walter Danielczyk, Karl Heinz Tragl, Peter 
Fischer, Peter Riederer, Edna Grünblatt; BMC Medical Genetics 2011, 12:151 
 
 
Abstract 
 
Background: Insulin-degrading enzyme (IDE) is the ubiquitously expressed enzyme 
responsible for insulin and amyloid beta (Aβ) degradation. IDE gene is located on 
chromosome region 10q23-q25 and exhibits a well-replicated peak of linkage with Type 2 
diabetes mellitus (T2DM). Several genetic association studies examined IDE gene as a 
susceptibility gene for Alzheimer‟s disease (AD), however with controversial results. 
Methods: We examined associations of three IDE polymorphisms (IDE2, rs4646953; IDE7, 
rs2251101 and IDE9, rs1887922) with AD, Aβ42 plasma level and T2DM risk in the 
longitudinal Vienna Transdanube Aging (VITA) study cohort. 
Results: The upstream polymorphism IDE2 was found to influence AD risk and to trigger the 
Aβ42 plasma level, whereas the downstream polymorphism IDE7 modified the T2DM risk; no 
associations were found for the intronic variant IDE9. 
Conclusions: Based on our SNP and haplotype results, we delineate the model that IDE 
promoter and 3‟ untranslated region/downstream variation may have different effects on IDE 
expression, presumably a relevant endophenotype with disorder-specific effects on AD and 
T2DM susceptibility. 
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ABSTRACT MANUSCRIPT II 
 
Alzheimer’s disease and Type 2 Diabetes: two diseases, one common link? 
 
Bartl Jasmin, Monoranu Camelia-Maria, Wagner Anne-Kristin, Kolter Jann, Riederer Peter, 
Grünblatt Edna; The World Journal of Biological Psychiatry, 2012; 00: 1–8 
 
 
Abstract 
 
Objectives: Although Alzheimer‟s disease (AD) is the most common form of dementia in the 
elderly, its aetiology remains mostly unknown. A potential pathophysiological mechanism for 
AD arises from the knowledge that insulin is also synthesized independently in the central 
nervous system and is involved in the regulation of memory formation. AD may represent a 
brain-specific form of insulin resistance. 
Methods: We used immunohistochemistry to investigate the numbers of cells expressing 
insulin receptor β-subunit (IRβ) and phosphorylated PPARγ (PPARγ(p)) in human post-
mortem tissue from patients with AD; AD combined with type 2 diabetes mellitus (T2DM); 
just T2DM, and from aged-matched controls. These numbers were evaluated in frontal cortex 
and in dorsal/ ventral parts of the hippocampus. 
Results: We observed significantly lower numbers of IRβ positive cells in AD cases 
compared to all other groups in all investigated brain regions. Also significantly more 
PPARγ(p) positive cells occurred in each patient group compared to control. 
Conclusions: T2DM and AD may not be directly linked, but may share common histological 
features including lower numbers of IRβ positive cells and higher numbers of PPARγ(p) 
positive cells in all investigated brain regions. These observations may at least partially 
explain the increased frequency of AD in elderly diabetic patients. 
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ABSTRACT MANUSCRIPT III 
 
Different effects of soluble and aggregated Amyloid β42 on gene/ protein 
expression and enzyme activity involved in insulin and APP pathways 
 
Jasmin Bartl, Andrea Meyer, Svenja Brendler, Peter Riederer, Edna Grünblatt  
under Revision at Journal of Neural Transmission
 
 
 
Abstract 
 
Although Alzheimer‟s dementia (AD) is not anymore characterised just by the accumulation 
and deposition of amyloid beta (Aβ) peptides and hyperphosphorylation of tau proteins within 
the brain, excessive Aβ42 deposition is still considered to play a major role in AD. Aβ are able 
to adopt many differently aggregate forms, including amyloid fibrils as well as nonfibrillar 
structures (soluble Aβ42 oligomers). It is not well established which Aβ42 state is most 
responsible for AD or why. We wanted to verify, which effects Aβ42 oligomers and 
aggregated peptides have on gene expression, protein level and enzyme activity of insulin and 
amyloid precursor protein (APP) pathways in vitro. Human neuroblastoma cells (SH-SY5Y) 
were treated with varying concentrations of soluble and aggregated Aβ42. Treatment effects on 
-secretase (BACE), glycogen synthase kinase 3α (GSK3α), glycogen synthase kinase 3 
(GSK3), phosphatidylinisitol-3 kinase (PI-3K), insulin degrading enzyme (IDE), insulin 
receptor substrate 1 (IRS1), insulin receptor (INSR) and monoamine oxidase B (MAO-B) was 
investigated via quantitative-PCR, western blot, ELISA and enzyme activity assay. We could 
find different effects of soluble and aggregated peptides especially on gene/ protein 
expression of GSK3β and INSR and on GSK3β and MAO-B activity. Soluble peptides 
showed significant effects leading to increased gene expression and protein amount of GSK3β 
and to decreased level of gene and protein expression of INSR. MAO-B activity was 
enhanced after treatment with aggregated peptides and strongly inhibited after soluble Aβ42 
treatment. Our data might provide insights into selective effects of specific forms of A42 
aggregates in AD. 
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RESEARCH ARTICLE Open Access
Disorder-specific effects of polymorphisms at
opposing ends of the Insulin Degrading Enzyme
gene
Jasmin Bartl1*†, Claus-Jürgen Scholz2†, Margareta Hinterberger3, Susanne Jungwirth3, Ildiko Wichart3,
Michael K Rainer3, Susanne Kneitz2, Walter Danielczyk3, Karl H Tragl3, Peter Fischer3,4, Peter Riederer1,3 and
Edna Grünblatt1,3,5
Abstract
Background: Insulin-degrading enzyme (IDE) is the ubiquitously expressed enzyme responsible for insulin and
amyloid beta (Ab) degradation. IDE gene is located on chromosome region 10q23-q25 and exhibits a well-
replicated peak of linkage with Type 2 diabetes mellitus (T2DM). Several genetic association studies examined IDE
gene as a susceptibility gene for Alzheimer’s disease (AD), however with controversial results.
Methods: We examined associations of three IDE polymorphisms (IDE2, rs4646953; IDE7, rs2251101 and IDE9,
rs1887922) with AD, Ab42 plasma level and T2DM risk in the longitudinal Vienna Transdanube Aging (VITA) study
cohort.
Results: The upstream polymorphism IDE2 was found to influence AD risk and to trigger the Ab42 plasma level,
whereas the downstream polymorphism IDE7 modified the T2DM risk; no associations were found for the intronic
variant IDE9.
Conclusions: Based on our SNP and haplotype results, we delineate the model that IDE promoter and 3’
untranslated region/downstream variation may have different effects on IDE expression, presumably a relevant
endophenotype with disorder-specific effects on AD and T2DM susceptibility.
Background
Insulin degrading enzyme (IDE), also known as insuly-
sin, insulin protease or insulinase, is a 110 kDA zinc-
dependent metalloprotease of the M16A subfamily,
which is coded by a 122 kb spanning, ubiquitously
expressed gene on the distal region of the human chro-
mosome 10 q [1]. Apart from its primary target insulin,
IDE competitively hydrolyzes multiple proteins including
glucagon, atrial natriuretic factor, transforming growth
factor-a, and b-endorphin amylin [2,3] These facts sug-
gest a potentially wide role for IDE in the clearance of
hormones and bioactive peptides. In addition to its role
in insulin catabolism, IDE has been found to degrade b-
amyloid (Ab) 40 and 42 and the amyloid precursor
protein (APP) intracellular domain and to eliminate
Ab42 neurotoxic effects [4]. The first evidence that IDE
might be involved in Ab42 degradation was found by
Kurochkin and Goto in 1994, who demonstrated that
purified rat IDE efficiently degrades synthetic Ab42 in
vitro [3]. Subsequently, it was shown that an IDE-like
activity from soluble and synaptic membrane fractions
of postmortem human brain both degrade Ab42 peptides
[5,6]; moreover, IDE doesn’t distinguish between endo-
genous and synthetic Ab42 as substrate in vitro [7]
The fact that extracellular Ab42 deposition is one of
the hallmarks of the neurodegenerative disorder Alzhei-
mer’s disease (AD) made IDE a promising candidate
involved in disease susceptibility. Several studies asso-
ciated linkage-peaks over the IDE region with late-onset
AD (LOAD) [8], age of onset in familial AD [9] and
high plasma Ab42 levels [10]. Furthermore, validated
linkage peaks with the metabolic syndrome Type 2
* Correspondence: e_bartl_j@klinik.uni-wuerzburg.de
† Contributed equally
1Department of Psychiatry, Psychosomatic and Psychotherapy, University
Hospital of Wuerzburg, Fuechsleinstr. 15, D-97080 Wuerzburg, Germany
Full list of author information is available at the end of the article
Bartl et al. BMC Medical Genetics 2011, 12:151
http://www.biomedcentral.com/1471-2350/12/151
© 2011 Bartl et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Diabetes Mellitus (T2DM) were found in the same
region [11,12]. Fakhrai-Rad and colleagues narrowed
down the wide range of possible candidate genes to IDE
via transferring the gene from an inbred rat model of
T2DM to a normoglycemic rat, which resulted in the
recapitulation of several diabetic features, including
hyperinsulinemia and postprandial hyperglycemia [13].
In the present study, we undertook an attempt to
associate selected variants of the IDE gene with AD,
Ab42 plasma levels and T2DM in participants of the
Vienna Transdanube Aging (VITA) longitudinal cohort
study.
Methods
Subjects
Subjects of the present study were from the VITA study
which was described previously in greater detail [14,15].
The VITA study investigated the residents of two Vien-
nese districts born between May 1925 and June 1926 (i.
e., aged 75 years at inclusion). Data refer to the total
cohort at baseline recruitment of 606 individuals who
completed physical health check, questionnaires for edu-
cation, psychosocial activities and neuropsychological
examination. The 1st follow-up after 30 months included
468 subjects performing the full health check at the
Danube hospital and 30 subjects that were either exam-
ined at home or interviewed on the phone. Further 70
subjects refused to attend the follow-up and 38
deceased. At the 2nd follow-up after 60 months 362
subjects attended the full health check at the Danube
hospital, whereas 68 subjects were visited at home or
only willing to take part in a telephone-interview, thus
providing only minimal information. 81 subjects out of
the 606 participants deceased between baseline and the
2nd follow-up investigation, 92 subjects refused to take
part again and in three cases no contact was possible to
establish. A diagnosis of AD was established applying
the NINCDS-ADRDA criteria [16]. All participants
passed through a consensus conference with regard to
the diagnoses of possible or probable AD. The final
diagnosis was made by an experienced geronto-psychia-
trist. Since the NINCDS-ADRDA diagnosis requires
longitudinal information, at baseline all demented sub-
jects were considered as AD positive. In rare cases (n =
16), later (and thus more reliable) examinations revealed
“no AD” diagnoses in subjects previously diagnosed as
AD positive. For the present analysis, these subjects
were treated as AD negative up to the last “no AD”
diagnosis. Additional information was obtained in all
cases for relevant serum parameters such as cortisol and
glucose level and T2DM was diagnosed according to the
guide line of the world health organisation. One partici-
pant was diagnosed with an untreated schizophrenia;
this subject was excluded from AD analyses, however
retained in T2DM analyses due to absence of anti-schi-
zophrenic medication, which is known to increase
T2DM susceptibility. Additional file 1 - “Demographic
information of the VITA study cohort” gives an over-
view of the subjects examined in this study.
The VITA study was carried out with the permission
of the Ethics Committee of the City of Vienna, Austria
and each participant gave a written informed consent.
DNA extraction
DNA was prepared from 2 ml EDTA-blood as pre-
viously described [15]. Finally, the DNA was aliquoted
into cryo-vials (NUNC, Langenselbold, Germany) and
stored frozen at -70 C till requirement.
IDE SNP selection and genotyping
The most validated IDE SNPS were selected after publi-
cation research for association studies in AD and T2DM
[17-20]. The IDE genotypes were determined using Taq-
Man assay with the real time PCR reaction using speci-
fic primers from TaqMan single nucleotide
polymorphism (SNP) Genotyping Assay (Applied Biosys-
tems, Darmstadt, Germany), which uses the 5’ nuclease
assay for amplifying and detecting specific SNP alleles in
purified genomic DNA samples. C_22272896_10 (IDE2,
rs4646953), C_27104906_10 (IDE7, rs2251101) and
C_12116624_10 (IDE9, rs1887922) assays were used for
SNP typing. Analysis of the genotypes was conducted
on the iCycler software with allelic discrimination pro-
gram (Bio-Rad, Munich, Germany).
Ab1-42 plasma level
Plasma levels of amyloid were determined by a double-
antibody sandwich enzyme-linked immunosorbent assay
method (Innogenetics NV, Ghent, Belgium). The
INNOTEST b-amyloid (1-42) allows the specific and
reliable measurement of (1-42) amyloid peptides in
plasma [21]. The detection range is 5-1000 pg/ml.
Statistical analysis
Prior to association analysis, IDE SNPs were tested for
Hardy-Weinberg equilibrium (HWE) with a one degree
of freedom c2-test; no significant departures were
detected (all p-values > 0.001). Associations in the dif-
ferent time points were tested with logistic regression
when the outcome variable was binary (no/yes), or with
linear regression when influence on a continuous out-
come was examined. For longitudinal association analy-
sis, generalized estimating equations were used.
Genotypic associations were performed using three dif-
ferent models: in the additive model, each individual’s
risk allele count entered the regression; the dominant
model considered the presence of at least one risk allele
and in the recessive model, a genotypic risk was only
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present if the individual was homozygous for the risk
allele. The Akaike Information Criterion (AIC) was used
to choose the best model. In single SNP analysis the
polymorphism’s minor allele was assumed to be the risk
allele; all minor allele frequencies were above our inclu-
sion threshold of 5%. In haplotype analysis, each haplo-
type allele was tested against all other alleles; to account
for phase uncertainty, each allele’s posterior probability
was incorporated into the model. Haplotypes were
defined with the expectation-maximization algorithm
[22]. Individuals with any missing values in IDE geno-
types (n = 38 of 606 in the original VITA cohort) were
removed from haplotype analyses. Only common haplo-
types with a frequency of at least 5% were analyzed.
Associations were considered to be significant at a =
0.05; due to the limited sample size of this study, the
reported nominal p-values were not adjusted for multi-
ple testing. Power estimates for the determined effect
sizes refer to the described analysis settings and result
from the comparison of test statistic distributions under
the null and alternative hypothesis. All association and
power analyses were performed in R version 2.10.0
using the packages geepack, pwr, powerMediation and
SimHap (all obtained from http://www.r-project.org).
Results
We examined the associations of IDE SNPs (IDE2,
rs4646953; IDE7, rs2251101; IDE9, rs1887922) and
derived haplotypes (on the coding strand in genomic
order 5 ’-IDE2-IDE9-IDE7-3 ’) with AD and Ab42
plasma levels, as well as with T2DM in unrelated sub-
jects participating in the VITA longitudinal cohort
study. Further information can be found in Additional
file 2 - “Insulin degrading enzyme genotype distribu-
tions and tests for Hardy-Weinberg equilibrium” and
Additional file 3 -"Power calculations for examined
markers and outcomes”.
Insulin degrading enzyme polymorphisms and Alzheimer’s
disease
Genetic associations of IDE with AD used dominant
models. In order to prove the independence of the
observed effects from known risk factors like presence
of APOE ε4 alleles and female sex, respectively, those
covariates were included in multivariate regressions.
This revealed a significant association of IDE2 (p = 0.03,
see Table 1) in subjects that attended the 60 months fol-
low-up (t = 60). The minor allele (C on the coding
strand) was found to have a protective effect (OR =
0.55); longitudinally, the effect size did not undergo sig-
nificant monotonic changes over time (p = 0.41, see
Table 1). Results from haplotype analysis reflect the
findings of single marker analysis in that the haplotype
that carries the IDE2 risk allele together with the major
alleles of IDE9 and IDE7 is also associated with AD at t
= 60 (see Table 2): haplotype CAA conveys a signifi-
cantly (p = 0.02) protective ( OR = 0.5) effect. As in sin-
gle marker analysis, the observed effect size did not
undergo significant monotonic changes over time (see
Table 2).
Insulin degrading enzyme polymorphisms and amyloid b42
plasma level
We then examined the additive influence of IDE SNP
alleles and haplotypes on the endophenotype Ab42
plasma level. Multivariate regressions included APOE ε4
Table 1 Association results of insulin degrading enzyme SNPs
AD Ab42 plasma level [pg/ml] T2DM
Polymorphism (major/minor allele) focus OR (95% CI) p-value slope (95% CI) p-value OR (95% CI) p-value
IDE2 (T/C) baseline - - 22.36 (8.08 - 36.6) 0.002 0.82 (0.23 - 2.86) 0.75
IDE2 (T/C) 1st follow-up 0.66 (0.36 - 1.21) 0.18 21.04 (2.08 - 40) 0.03 0.96 (0.3 - 3.05) 0.95
IDE2 (T/C) 2nd follow-up 0.55 (0.32 - 0.95) 0.03 35.26 (12.8 -57.8) 0.002 1.32 (0.41 - 4.24) 0.64
IDE2 (T/C) × examination longitudinal 1.13 (0.84 - 1.43) 0.41 8.23 (1.93 -14.5) 0.01 1.27 (0.81 - 1.73) 0.31
IDE7 (A/G) baseline 1.74 (0.63 - 4.78) 0.28 -5.24 (-16.7 - 6.2) 0.37 2.4 (1.25 - 4.63) 0.009
IDE7 (A/G) 1st follow-up 1.26 (0.77 - 2.07) 0.35 -5.31 (-21 -10.3) 0.51 2.62 (1.32 - 5.18) 0.006
IDE7 (A/G) 2nd follow-up 0.97 (0.62 - 1.52) 0.89 -14.27 (-33.7 - 5.2) 0.15 3.47 (1.72 - 6.97) 0.0005
IDE7 (A/G) × examination longitudinal 0.86 (0.56 - 1.16) 0.33 -3.37 (-8.2 - 1.49) 0.18 1.1 (0.91 - 1.3) 0.32
IDE9 (A/G) baseline 1.87 (0.71 - 4.92) 0.21 -7.36 (-19.5 - 4.8) 0.24 1.65 (0.72 - 3.79) 0.24
IDE9 (A/G) 1st follow-up 1.02 (0.62 - 1.69) 0.94 -8.39 (-24.9 - 8.1) 0.32 1.17 (0.46 - 3.0) 0.75
IDE9 (A/G) 2nd follow-up 0.99 (0.62 - 1.58) 0.96 -11.1 (-31.8 - 9.7) 0.3 1.75 (0.7 - 4.37) 0.23
IDE9 (A/G)× examination longitudinal 0.88 (0.57 - 1.19) 0.42 -0.85 (-5.5 - 3.83) 0.72 0.98 (0.78- 1.17) 0.81
Insulin degrading enzyme (IDE) SNPs (IDE2, rs4646953; IDE7, rs2251101; IDE9, rs1887922) were associated with Alzheimer’s disease (AD), amyloid b42 (Ab42) plasma
levels and Type 2 diabetes mellitus (T2DM). Effect sizes and nominal p-values were derived from multivariate regression analysis with sex and presence of
apolipoprotein E (APOE ε4) alleles as covariates in regressions on AD affection and Ab42 plasma level, respectively. T2DM affection as outcome used sex and BMI
as covariates. Longitudinal analysis examined interactions of all covariates with the examination (baseline, 1st and 2nd follow-up). Associations were calculated
using dominant models for AD, additive models for Ab42 plasma level and recessive models for T2DM. Nominally significant p-values (p < 0.05) are shown in
bold.
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status and sex as covariates. The analyses concordantly
revealed that with each minor C allele of IDE2 the Ab42
plasma level increases between 21.04 and 35.26 pg/ml,
depending on time point of analysis (see Table 1 and
Figure 1A). This finding was significant in all time
points (see Table 1). Longitudinal analysis revealed that
the observed effect significantly (p = 0.01) increased
with each follow-up by 8.23 pg/ml (see Table 1). Of
note, an increase in Ab42 plasma level was not exclusive
to IDE2 risk allele carriers, but was also observed in
individuals homozygous for the major allele (see Table 3
and Figure 1). Since an increased Ab42 plasma level is a
known risk factor for AD, we also examined the interac-
tion of the IDE2 genotype with the AD disease status on
the Ab42 plasma level. The effect sizes at t = 30 and t =
60 reveal that the IDE2 C allele as well as AD affection
both lead to an increased Ab42 plasma level, however
that the combined effect is much more pronounced
than the sum of both effects (see Table 4 and see Figure
1B). However, the effects for AD and its interaction
with the IDE2 genotype are only significant at t = 60,
while the effect of IDE2 alone reaches only marginal sig-
nificance (see Table 4). On multimarker level, we found
each CAA haplotype to significantly increase the Ab42
plasma level between 25.93 and 41.5pg/ml, depending
on time point of analysis (see table 3B). Longitudinally,
we observed no increasing haplotype effect on Ab42
plasma level between examinations (see Table 2).
Insulin degrading enzyme polymorphisms and type 2
diabetes mellitus
Genetic associations of IDE with T2DM used recessive
models. In order to prove the independence of the
observed effects from known risk factors like body mass
index (BMI) and female sex, those covariates were
included in multivariate regressions. In all three time
points, we found the minor G allele of IDE7 to bear a
significant (p<0.01) genotypic risk to develop T2DM,
with an initial (t = 0) OR of 2.4, that continually
increased slightly (OR = 1.1) but not significantly (p =
0.32) to 3.47 at t = 60 (see Table 1). Haplotype analyses
revealed the association of haplotypes TAG and TGG
with T2DM, in case of the first in all three time points,
in case of the second only at t = 0 and t = 60 (see Table
2). In line with the single marker result for IDE7, both
haplotypes convey a genetic risk to become diabetic
with significant effect sizes ranging from 3.25 to 3.28 for
TGG and from 6 to even 13 for TAG, depending on
Table 2 Association results of insulin degrading enzyme haplotypes
haplotype AD Ab42 plasma level [pg/ml] T2DM
5’ IDE2 IDE9 ’3 IDE7 focus OR (95% CI) p-value Slope (95% CI) p-value OR (95% CI) p-value
T A A baseline 2.01 (0.46 -9.47) 0.34 -5.8 (-16.1 - 4.5) 0.27 1.01 (0.63 -1.61) 0.98
T A A 1st follow-up 1.96 (0.98 - 3.9) 0.06 -5.33 (-19.5- 8.86) 0.46 0.83 (0.5 - 1.38) 0.46
T A A 2nd follow-up 1.51 (0.85 -2.68) 0.16 -7.37 (-24.7 -9.95) 0.41 0.92 (0.54 -1.59) 0.78
T A
× examination
A longitudinal 0.94 (0.63 -1.41) 0.77 -0.05 (-0.18- 0.07) 0.4 0.95 (0.84 -1.07) 0.41
T G G baseline 2.23 (0.82 -6.1) 0.12 -6.98 (-20.4- 6.47) 0.31 3.25 (1.31 -8.04) 0.01
T G G 1st follow-up 1.03 (0.61 -1.74) 0.92 -6.78 (-25.1-11.6) 0.47 2.22 (0.81- 6.05) 0.12
T G G 2nd follow-up 0.93 (0.56 -1.53) 0.78 -12.06 (-35.3-1.17) 0.31 3.28 (1.2 - 8.99) 0.02
T G
× examination
G longitudinal 0.82 (0.59 -1.14) 0.25 -0.01 (-0.23- 0.21) 0.92 0.99 (0.79 -1.24) 0.93
T A G baseline 0.91 (0.25 -3.26) 0.89 -0.62 (-17.9-16.7) 0.94 6.0 (1.29 -27.7) 0.02
T A G 1st follow-up 1.22 (0.66 -2.26) 0.52 -0.75 (-25.13-23.6) 0.95 13.0 (1.47-129.33) 0.02
T A G 2nd follow-up 1.02 (0.57-1.83) 0.94 -13.76 (-43-15.48) 0.36 8.66 (1.54 -48.77) 0.01
T A
× examination
G longitudinal 0,99 (0.69- 1.43) 0.97 0.24 (-0.45- 0.94) 0.49 1.28 (0.64 - 2.6) 0.49
C A A baseline - - 26.36 (10.84-41.88) 0.001 0.34 (0.04 -2.63) 0.3
C A A 1st follow-up 0.65 (0.34-1.23) 0.18 25.93 (5.21-46.64) 0.01 0.59 (0.12 -2.82) 0.51
C A A 2nd follow-up 0.5 (0.28- 0.88) 0.02 41.5 (17 - 66) 0.001 0.87 (0.18- 4.14) 0.86
C A
× examination
A longitudinal 1.08 (0.81-1.46) 0.59 0.23 (-0.38 -0.86) 0.45 1.26 (0.69 -2.32) 0.45
Insulin degrading enzyme (IDE) haplotypes (IDE2, rs4646953; IDE7, rs2251101; IDE9, rs1887922) with frequencies > 5% were associated with Alzheimer’s disease
(AD), amyloid b42 (Ab42) plasma levels and Type 2 diabetes mellitus (T2DM). Effect sizes and nominal p-values were derived from multivariate regression analysis
with sex and presence of apolipoprotein E (APOE ε4) alleles as covariates in regressions on AD affection and Ab42 plasma level, respectively. T2DM affection as
outcome used sex and BMI as covariates. Longitudinal analysis examined interactions of all covariates with the examination (baseline, 1st and 2nd follow-up).
Associations were calculated using dominant models for AD, additive models for Ab42 plasma level and recessive models for T2DM. Nominally significant p-
values (p < 0.05) are shown in bold.
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time point of analysis (see Table 2). Longitudinally, the
associated haplotypes did not exhibit significant mono-
tonic changes in effect sizes (see Table 2).
Discussion
The identification of a late-onset AD risk locus on chro-
mosome 10q which also affects plasma Ab42 levels, has
led to the search for functional candidates in this region
[8,10]. Because of its mapping to the AD linkage peak
and of the ability of its gene product to degrade Ab42,
IDE was proposed to harbour a plausible origin for the
observed effects. Since IDE is also well-known to be
associated with increased risk for T2DM [12,23,24], the
present study aimed at examining the effects of selected
common IDE polymorphisms on both disease outcomes
Figure 1 Amyloid b42 (Ab42) plasma levels [pg/ml]. A) in insulin degrading enzyme IDE2 SNP (rs4646953) genotypes and B) in IDE2
genotypes stratified by Alzheimer’s disease (AD) status (AD no/yes) at baseline, 1st and 2nd follow-ups.
Table 3 Longitudinal analysis of amyloid b42 (Ab42)
plasma levels in different insulin degrading enzyme 2
(SNP rs4646953) genotypes
IDE2 genotype Ab42 plasma level [pg/ml]
slope (95% CI) p-value
all genotypes 23.7 (20.34 - 27.07) < 2 ∙ 10
only T/T 21.33 (17.73 - 24.94) < 2 ∙ 10-16
only T/C 25.84 (16.52 - 35.17) 5.6 ∙ 10-8
only C/C 43.28 (27.7 - 58.86) 5.23 ∙ 10-8
Effect sizes and nominal p-values were derived from multivariate regression
analysis with sex and presence of apolipoprotein E (APOE ε4) alleles as
covariates. All IDE2 (SNP rs4646953) genotype groups display a highly
significant increase in Ab42plasma concentration between each of the three
examinations.
Table 4 Interaction analysis of insulin degrading enzyme
2 (SNP rs4646953) genotype
parameter (baseline/
risk)
examination slope (95% CI) p-
value
IDE2 (T/C) baseline 20.72 (6.23 - 35.21) 0.005
AD (no/yes) -7.45 (-50.34 - 35.45) 0.73
IDE2 × AD - -
IDE2 (T/C) 1st follow-up 13.60 (-6.92 - 34.11) 0.19
AD (no/yes) 7.36 (-23.75 - 38.48) 0.64
IDE2 × AD 33.91 (-22.02 -
89.84)
0.24
IDE2 (T/C) 2nd follow-
up
21.41 (-3.43 - 46.25) 0.09
AD (no/yes) 36.27 (3.72 - 68.82) 0.03
IDE2 × AD 76.89 (24.01 -
129.77)
0.005
Analysis of interaction of insulin degrading enzyme SNP rs4646953 (IDE2)
genotype and Alzheimer’s disease (AD) status on amyloid b42 (Ab42) plasma
level is shown. Effect sizes and nominal p-values were derived from
multivariate regression analysis with sex and presence of apolipoprotein E
(APOE ε4) alleles as covariates. Nominally significant p-values (p < 0.05) are
shown in bold.
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as well as on the plasma Ab42 level in subjects partici-
pating in the longitudinal VITA cohort study. The ana-
lyzed polymorphisms should serve as proxies to partly
capture the common allelic variation in the up- (IDE2)
and downstream (IDE7) region, as well as in the gene
body (IDE9) of IDE. Our finding that we were not able
to detect associations of IDE9 with neither examined
trait leads us to the hypothesis that common IDE var-
iants influencing the primary structure of the IDE pro-
tein (i.e. non-synonymous SNPs and those affecting
splicing junctions, respectively) may have no major
impact on AD and T2DM susceptibility. However,
despite extended linkage disequilibrium (LD) in the IDE
region (see Additional file 4 - “Linkage disequilibrium in
the insulin degrading enzyme region”), a single SNP may
not fully represent the allelic variation throughout the
gene. In fact, 13 tag SNPs of 45 SNPs genotyped in the
HapMap CEU panel (release 24) are needed to capture
the variation inside IDE with a mean r2 of 0.99 (data
not shown). Therefore the possibility remains that dele-
terious variants not in LD with IDE9 exist, e.g. rare IDE
variants with possibly large effects on our examined
traits. While this remains speculative, we found that
allelic variation at opposing ends of IDE is associated
with different outcomes: the upstream and 5’-untrans-
lated region (UTR) harbours polymorphisms presumably
modifying the AD disease risk and the Ab42 plasma
level, whereas 3’-UTR and downstream variants may
trigger T2DM susceptibility.
There is evidence that the IDE level and therefore
Ab42 degrading activity is lower in AD brains than in
those of unaffected subjects [6], which can be also an
effect of oxidative stress (OS). OS is considered to be a
key mechanism in the pathophysiology of AD and is
characterized by increased highly reactive oxygen species
(ROS) production and decreased antioxidant defence
[25,26]. Interestingly the catalytic activity of IDE is
reduced through ROS and also the enzymatic activity
toward Ab hydrolysis is decreased [27]. Nonetheless,
this has to be further investigated, as it might provide
additional link between AD and T2DM. Furthermore,
studies on pro-oxidants could be equally important in
order to develop new treatment avenues for AD.
A recent study of Zuo and Jia found that variants in
the proximal IDE promoter increase transcription and
thus provide a possible mechanism explaining the pro-
tective effect on AD susceptibility found for the exam-
ined polymorphisms [28]. Among those, IDE2
overlapped with our study, however with different
results: while we found an association with AD in our
Vienna-based cohort, IDE2 was not associated in the
mentioned Han Chinese sample. This reflects the situa-
tion in AlzGene meta-analyses, which list a slightly pro-
tective odds ratio (OR) of 0.93 for IDE2 in Central
European study populations and an overall OR of 1.0 (i.
e. no effect) if Asian studies are included [29]. This
makes clear that IDE2 is unlikely to be the causal var-
iant and furthermore raises the possibility that LD
between IDE2 and the presumed functional allele varies
between Central European and Asian populations. Given
this, our present study and that of Zuo and Jia [28]
agree that promoter variants leading to increased IDE
transcription protect against AD. Correspondingly, one
would expect Ab42 plasma levels to be lower in indivi-
duals carrying high expression variants, but intriguingly
our results show the opposite (see Table 1 and 2). This
contradicts the results from a recent study which found
high IDE expression variants to be correlated with lower
Ab plasma levels, however, Ab40 contributed more to
the observation than Ab42 [30]. Plasma Ab42 levels are
thus not reliably predicted by IDE polymorphisms alone,
because also trans-acting variants were shown to influ-
ence the expression of IDE [31]. Furthermore, due to
the wide range of IDE substrates, an important determi-
nant for Ab42 degrading activity is the concentration of
the primary IDE target (i.e. insulin), illustrated by the
finding that even Ab40 clearance is effectively inhibited
by insulin [32]. This notion is supported by our observa-
tion that a large proportion of the Ab42 plasma level is
explained by factors different from the IDE promoter
genotype (see Table 4).
Hallmarks of T2DM are the presence of insulin resis-
tance and insulin receptor insensitivities. Insulin resis-
tance precedes the onset of T2DM for years [33] and
results in compensatory hyperinsulinemia, which is the
first step to developing T2DM [34]. Limited capacities
to degrade increased plasma insulin levels contribute to
development of T2DM. Our association of the down-
stream variant IDE7 with T2DM might be an indirect
signal that extends from the IDE 3’-UTR over LD. The
presumed risk allele may attenuate translation or reduce
the stability of the IDE mRNA, thus challenging IDE
activity and promoting hyperinsulinemia, explaining the
increased T2DM susceptibility.
Based on these assumptions, we delineate the model
that polymorphisms at opposing ends of the IDE gene
may lead to expression changes with consequences on
susceptibility to different diseases: promoter variation
presumably increases IDE expression and protects from
AD, while 3’-UTR variation is assumed to decrease IDE
expression and to increase T2DM risk. Correspondingly,
haplotypes that carry both associated alleles on a single
DNA molecule (5’-CGG-3’ and 5’-CAG-3’) should reveal
a balanced (i.e. no) effect on AD and T2DM. Due to the
low frequencies of these haplotypes (0.5% and 0.2%, data
not shown) in the VITA study cohort, we were however
not able to reliably examine this balancing effect.
Despite the plausibility of the model in the context of
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the VITA study cohort, validation of the model clearly
requires further examinations, including the determina-
tion of the IDE activity, which is expected to provide
deeper insight into disease causing mechanisms [35].
Conclusions
Based on our SNP and haplotype results, we delineate
the model that IDE promoter and 3’-UTR/downstream
variation may have opposing effects on IDE expression,
which is assumed to be a relevant endophenotype with
disorder-specific effects on AD and T2DM susceptibility.
As a starting point for targeted investigations, the pre-
sent study provides insight how variation in the IDE
gene contributes to link the pathophysiologically differ-
ent diseases AD and T2DM.
Additional material
Additional file 1: Demographic information of the VITA study
cohort. Abbreviations used: AD = Alzheimer’s disease; BMI = body mass
index; SD = standard deviation; T2DM = Type 2 diabetes mellitus.
Additional file 2: Insulin degrading enzyme genotype distributions
and tests for Hardy-Weinberg equilibrium. Insulin degrading enzyme
(IDE) genotype distributions and tests for Hardy-Weinberg equilibrium
(HWE) in analysis subgroups defined by cross-sectional outcomes. No
significant departures from HWE were detected (all p > 0.001).
Additional file 3: Power calculations for examined markers and
outcomes. The presented additional file 3 indicate the power to find
nominally significant associations (p < 0.05) given analysis settings used
for the estimation of effect sizes shown in Tables 1 and 2. Abbreviations
used: Ab42 = amyloid beta 1-42 plasma concentration; AD = Alzheimer’s
disease; IDE2 = rs4646953; IDE7 = rs2251101; IDE9 = rs1887922; SNP =
single nucleotide polymorphism.
Additional file 4: Linkage disequilibrium in the insulin degrading
enzyme region. Linkage disequilibrium (LD) in the IDE gene region ± 10
kb is shown based on D’ values between single nucleotide
polymorphisms (SNPs) genotyped in the HapMap CEU panel (release 24).
LD colour scheme corresponds to default settings used in Haploview.
Positions of SNPs examined in the present study are indicated in blue. Of
note, rs4646953 (IDE2) has not been genotyped in the HapMap project,
therefore no LD information is available for this SNP.
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 Abstract 
 Objectives. Although Alzheimer ’ s disease (AD) is the most common form of dementia in the elderly, its aetiology remains 
mostly unknown. A potential pathophysiological mechanism for AD arises from the knowledge that insulin is also synthe-
sized independently in the central nervous system and is involved in the regulation of memory formation. AD may repre-
sent a brain-specifi c form of insulin resistance.  Methods . We used immunohistochemistry to investigate the numbers of cells 
expressing insulin receptor  β -subunit (IR β ) and phosphorylated PPAR γ (PPAR γ (p)) in human post-mortem tissue from 
patients with AD; AD combined with type 2 diabetes mellitus (T2DM); just T2DM , and from aged-matched controls. 
These numbers were evaluated in frontal cortex and in dorsal/ventral parts of the hippocampus.  Results. We observed sig-
nifi cantly lower numbers of IR β positive cells in AD cases compared to all other groups in all investigated brain regions. 
Also signifi cantly more PPAR γ (p) positive cells occurred in each patient group compared to control.  Conclusions . T2DM 
and AD may not be directly linked, but may share common histological features including lower numbers of IR β positive 
cells and higher numbers of PPAR γ (p) positive cells in all investigated brain regions. These observations may at least par-
tially explain the increased frequency of AD in elderly diabetic patients. 
 Key words: Alzheimer ´ s disease ,  type 2 diabetes mellitus ,  insulin receptor  β subunit ,  phosphorylated PPAR γ ,  immunohistochemistry 
staining 
 Introduction 
 The association between type 2 diabetes mellitus 
(T2DM) and increased risk of dementia in the elderly 
is well documented (Biessels and Kappelle 2005; 
de la Monte and Wands 2005). Multiple possible 
mechanisms for this association have been proposed, 
including the direct effects of hyperglycaemia, insulin 
resistance, and insulin-induced amyloid-peptide amy-
loidosis in the brain (Luchsinger and Gustafson 2009). 
Alzheimer ’ s disease (AD) is the most common form 
of dementia in the elderly; despite decades of intense 
research, the aetiology of AD remains mostly unknown. 
Since insulin is also synthesised in the central nervous 
system and is involved in the regulation of several cell 
processes including memory formation, it may con-
tribute to an underlying pathophysiological mecha-
nism for AD. 
 An early correlation between insulin receptor 
 β -subunit (IR ß ) and AD arose in the mid-1980s 
when it was reported that the hippocampus and 
parts of the cerebral cortex, regions important to 
learning and memory, contained high densities of 
IR β (Gammeltoft et al. 1985; Baskin et al. 1987). 
Insulin has dramatic effects on human cognition 
(Strachan et al. 1997), and the actions of insulin and 
insulin-sensitising peroxisome proliferator-activated 
receptor- γ (PPAR γ ) agonists have been explored in 
AD patients (Watson and Craft 2003). The risk of 
AD and memory impairments is increased by hyper-
insulinaemia and insulin resistance, characteristics of 
T2DM (de la Monte 2009; Carlsson 2010), which 
is associated with an increased risk of AD (Sims-
Robinson et al. 2010). These observations and other 
fi ndings have led to the hypothesis that the cognitive 
defi cits observed in AD may arise, in part, from insu-
lin insensitivity in the brain. 
 Glucose uptake and metabolism have been shown 
to be impaired in brain regions involved in memory 
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in 10 mM citrate buffer cointaing 10.51 g citrate 
monohydrate and 2 g sodium hydroxide pellets in 5 l 
double distillate water (pH 6) for at least 10 min for 
antigen retrieval. The sections were washed three 
times in Tris-buffered saline, and non-specifi c binding 
was blocked with blocking solution containing 10% 
normal goat serum, 2% bovine serum albumin, and 
0.01% Triton X-100 in Tris-buffered saline for 1 h 
before incubation with the various primary antibodies 
diluted in blocking solution. The primary antibodies 
targeted the following proteins: IR β (Santa Cruz, 
Heidelberg, Germany), diluted 1:200; neuronal spe-
cifi c enolase (NSE; Abcam, Cambridge, UK), diluted 
1:300; and PPAR γ (p) (Abcam, Cambridge, UK), 
diluted 1:200 and all antibodies were incubated over-
night at 4 ° C. The primary antibodies were visualised 
with antibodies conjugated to Alexa ® Fluor-488 
(green) and Fluor-555 (red; Invitrogen, Darmstadt, 
Germany). All secondary antibodies were incubated 
for 2 h at room temperature in the dark. Finally, the 
sections were mounted on glass slides and cover 
slipped under Vectashield (Vector Labs, Eiching, Ger-
many) for fl uorescence microscopy. 
 Automated cell counting 
 Five images of each brain region from each patient 
were recorded and analysed with Cell^P (version 2.0; 
Olympus, Hamburg, Germany). We used Imaging C 
within Cell^P to use a macro recorder, to defi ne spe-
cial regions of interest for each investigated protein, 
and to perform automated cell counting. The total 
cell number for each image was determined, and we 
separately obtained counts for the special regions of 
interest for each image. Automated cell counting 
helped us maintain the standard error of measure-
ment at the same level for image analyses. 
 Statistical analysis 
 Immunohistochemistry images were analysed for the 
numbers of cells positive for NSE, IR β , and PPAR γ (p) 
staining in comparison to the total number of cells via 
analysis of variance (ANOVA) and a post-hoc Scheff é 
test with a signifi cance level of  P    0.05. Reported val-
ues were calculated in relative to control levels (100%). 
The statistical program Stat View 5.0 (SAS Institute 
Inc. Cary, NC, USA) was used for all analyses. 
 Results 
 Figure 1 represents one example of histochemical 
staining for NSE in the prefrontal cortex of a control 
case. Fluorescent pictures were always recorded in 
gray values for counting. Each protein had its own 
and cognition in AD patients (Arnaiz et al. 2001; 
Watson and Craft 2004). For example, insulin can 
act both  in vitro and in AD patients to regulate 
 amyloid  β (A β ) levels, and insulin may facilitate 
A β release and interfere with insulin degrading 
enzyme (IDE)-mediated degradation of A β (Qiu 
and Folstein 2006). In addition, vascular dysfunc-
tion associated with insulin resistance may also 
increase susceptibility to AD (Sa-Roriz et al. 2009; 
Umegaki 2009). The principal action of PPAR γ ago-
nists in the periphery of the body is to enhance insu-
lin sensitivity and lower serum glucose levels, actions 
that underlie the effi cacy of these drugs (Berger and 
Wagner 2002) and provide a rationale for the use of 
PPAR γ agonists in treating AD. 
 In this study, we focused on IR β and phosphory-
lated PPAR γ producing cells in human post-mortem 
brain tissue. Using immunohistochemical staining 
against IR β and PPAR γ (p) in brain tissue originating 
from patients with AD, with AD combined with 
T2DM, with T2DM, and from aged-matched con-
trols, we evaluated the alterations of these proteins 
in the frontal cortex and in the dorsal and ventral 
parts of the hippocampus. 
 Materials and methods 
 Sample preparation 
 The brain samples used in this study were supplied 
by Brain Net Europe. The entire procedure was per-
formed in accordance with the Helsinki Declaration 
in its latest version and with the Convention of the 
Council of Europe on Human Rights and Biomedi-
cine. Clinical diagnosis of AD was based on NINCDS-
ADRDA criteria and confi rmed by neuropathological 
fi ndings (Braak and Braak 1991). 
 Histological samples were obtained from the dorsal 
and ventral hippocampus and from the prefrontal 
cortex of post-mortem brains from four patient 
groups (Supplementary Table 1 available online at 
http://www.informahealthcare.com/doi/abs/10.3109/
15622975.2011.650204): age-matched control patients 
without dementia, patients with T2DM, AD patients, 
and patients with AD plus T2DM. In preparation for 
routine neuropathological examination, the brain was 
divided midsagittally, and one hemisphere was 
immersed in 4.5%  p -formaldehyde (Fischer GmbH, 
Saarbruecken, Germany) for 3 – 4 weeks. 
 Immunohistochemistry 
 Paraffi n sections (8  μ m) of post-mortem brain tissue 
from the four patient groups were deparaffi ned with 
an alcohol dilution series. The slides were then boiled 
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regions in AD pathology, and for this reason we 
focused our IR β quantifi cation on these brain areas. 
Patients with AD had 50 – 60% fewer IR β positive 
cells in the prefrontal cortex ( P    0.0001) compared 
to the control group as well as compared to the 
patients group with only T2DM and to the 
AD   T2DM combined group (Figure 3). A 50% 
less IR β in the dorsal ( P    0.003) and 60% less IR β 
in the ventral hippocampus was found in comparison 
to the healthy control group ( P    0.0001) (Figure 3). 
While in the dorsal hippocampus we could fi nd only 
a tendency for less IR β positive cells in the AD group 
compared to the combined group ( T    0.063). On 
the other hand, in ventral hippocampus a nominal 
signifi cance reduction by 20% of IR β positive cells 
was detected in the AD group in comparison to the 
combined group ( P    0.0051) (Figure 3). Patients 
with T2DM alone possessed 32 – 35% fewer IR β 
positive cells in the dorsal hippocampus ( P    0.031) 
and ventral ( P    0.0103) compared to control sub-
jects (Figure 3); these values in the same brain 
regions were 26% ( P    0.0157) and 27% ( P    0.0154) 
for patients with AD plus T2DM (Figure 3). 
 Gender-based differences in the number of IR β 
positive cells were observed in AD patients (Supple-
mentary Table 2 available online at http://www.
informahealthcare.com/doi/abs/10.3109/15622975.
2011.650204). In all investigated brain regions, 
specifi c counting parameters, which were computa-
tionally defi ned for automated counting. 
 In order to ascertain that neuronal cell loss was 
not the predominant factor in our analysis of patient 
groups and control subjects, we stained all brain sec-
tion slides (prefrontal cortex, dorsal and ventral hip-
pocampus) with NSE antibody in all patient groups. 
In the prefrontal cortex we observed a minor but 
non-signifi cant difference in the number of enumer-
ated neurons in all three patients groups compared 
to the age-matched controls (Figure 2). AD patients 
had 17% fewer NSE positive cells, AD plus T2DM 
patients had 10% fewer NSE-positive cells, and 
T2DM patients had 15% fewer NSE-positive cells 
than the age-matched control subjects (Figure 2). 
Compared to the control group, the dorsal and ven-
tral hippocampus sections contained higher num-
bers of NSE positive cells in T2DM patients (24 – 28% 
more) and in patients with AD plus T2DM (14% 
more), but these differences were not statistically 
signifi cant (Figure 2). We used these brain regions 
for subsequent investigations because they were rel-
atively unaffected by neuronal cell lost in all groups, 
enabling identifi cation and confi rmation of specifi c 
protein alterations. 
 Cognitive function is an important parameter in 
the evaluation and determination of AD progression; 
the prefrontal cortex and hippocampus are critical 
 
Figure 1. Immunohistochemical staining of neuronal specifi c enolase (NSE) in the prefrontal cortex of a control case. Five fl uorescent 
images of each brain region were recorded for each case. The dashed area was included in the automated cell counting. (A) Cell nucleus 
stained in blue; (B) cell nucleus in gray values; (C) NSE staining in red; (D) NSE staining in gray values. The arrows point to the same 
structure in the fl uorescent and gray images. Scale bar size is 200 µm. 
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had 16% fewer positive cells, and in the ventral hip-
pocampus we observed 11% fewer positive cells. 
There was no signifi cant relationship between age 
and IR β level in any of the investigated brain regions 
female AD patients had signifi cantly fewer IR β -pos-
itive cells than male AD patients. In the prefrontal 
cortex females AD patients harboured 15% fewer 
IR ß positive cells, in the dorsal hippocampus they 
 
Figure 2. Neuronal specifi c enolase (NSE) positive cells in post-mortem human brain samples. Using immunohistochemical staining 
against NSE in brain tissue originating from patients with Alzheimer ’ s disease (AD), with AD combined with type 2 diabetes mellitus 
(T2DM), patients with T2DM alone, and age-matched controls, alterations in NSE positive cells in the prefrontal cortex and in the dorsal 
and ventral parts of the hippocampus were evaluated. No statistical differences were found between the three patient groups and the 
control group in any of the investigated brain regions. 
 
Figure 3. Insulin receptor (IR)  β -positive cells in post-mortem human brain samples. Using immunohistochemical staining against IR β 
in brain tissue originating from patients with Alzheimer ’ s disease (AD), with AD combined with type 2 diabetes mellitus (T2DM), patients 
with T2DM alone, and age-matched controls, alterations in NSE positive cells in the prefrontal cortex and in the dorsal and ventral parts 
of the hippocampus were evaluated. Statistical analysis of IR β positive cells was performed using ANOVA, post hoc Scheff é ; – – –    P    0.05; 
T= nominal signifi cance;  n    10 cases/group. (B) Immunohistochemical staining of IR β in hippocampus of a control case. Cell nucleus 
is stained in blue; IR β is stained in red. The arrows point to the right structure. Scale bar size is 200  μ m. 
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although marginal diabetics had a signifi cantly 
increased risk for future development of full diabe-
tes, dementia, or AD, the risk effects were indepen-
dent rather than linked (Xu et al. 2007). 
 In the present work we observed several common 
histological features in patients with diabetes and 
AD. In groups of patients with AD, with T2DM plus 
AD, and with T2DM alone, the number of IR β pos-
itive cells in the hippocampus was signifi cantly 
decreased compared to the control group (Figure 3). 
After evaluation of the total neuronal cell numbers 
in samples from all four groups, we were able to 
confi rm that the number of IR β positive cells was 
affected by AD and T2DM. 
 Why should AD or T2DM patients have fewer IR β 
positive brain cells compared to age-adapted con-
trols? AD is characterized both by low insulin levels 
and by insulin resistance within the central nervous 
system that causes a reduction in brain insulin. Sev-
eral mechanisms may explain why insulin mediates 
memory facilitation. As noted, insulin receptors are 
found in brain areas responsible for cognition. Insu-
lin activates signalling pathways associated with 
learning and long-term memory and helps to regu-
late processes such as neuronal survival, energy 
metabolism, and plasticity, processes that are required 
for learning and memory (Figure 5) (de la Monte 
and Tong 2009). Examination of post-mortem cases 
of late-stage AD demonstrated that advanced AD 
was associated with strikingly reduced levels of 
(Supplementary Table 3 available online at http://
www.informahealthcare.com/doi/abs/10.3109/
15622975.2011.650204). 
 The most signifi cant results involved the analysis 
of PPAR γ (p) positive cells. We detected more than 
60% more PPAR γ (p) positive cells in all patients 
group ( P    0.001) compared with the control group 
(Figure 4). There were no gender-specifi c differ-
ences in the number of PPAR γ (p) positive cells in 
the cortex, but analysis of the dorsal and ventral hip-
pocampus revealed signifi cant differences (Supple-
mentary Table 2 at http://www.informahealthcare.
com/doi/abs/10.3109/15622975.2011.650204.). 
Female patients with T2DM had 10% fewer PPAR γ (p) 
positive cells than male patients; in contrast, female 
AD patients possessed 13 – 18% more PPAR γ (p) pos-
itive cells in these brain regions. 
 Discussion 
 Accumulating evidence supports the hypothesis that 
AD and T2DM share a common link (de la Monte 
2009; Sa-Roriz et al. 2009; Sims-Robinson, Kim 
et al. 2010); while aging is clearly the strongest risk 
factor for AD, emerging data suggest that T2DM 
and dyslipidaemic states can contribute substantially 
to AD pathogenesis either directly or as cofactors 
(Qiu et al. 2007). Those observations are not without 
controversy, and a longitudinal survey revealed that 
 
Figure 4. A. Phosphorylated peroxisome proliferator-activated receptor- γ (PPAR γ (p))-positive cells in post-mortem human brain samples. 
Using immunohistochemical staining against PPAR γ (p) in brain tissue originating from patients with Alzheimer ’ s disease (AD), with AD 
combined with type 2 diabetes mellitus (T2DM), patients with T2DM alone, and age-matched controls, alterations in PPAR γ (p) positive 
cells in the prefrontal cortex and in the dorsal and ventral parts of the hippocampus were evaluated. Statistical analysis of PPAR γ (p) 
positive cells was performed using ANOVA; post hoc Scheff é - - -    P    0.0001;  n    10 cases/group. (B) Immunohistochemical staining 
of PPAR γ (p) in hippocampus of a control case. Cell nucleus is stained in blue; PPAR γ (p) is stained in red. The arrows point to the right 
structure. Scale bar size is 200  μ m. 
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that more IR β positive cells are detected than 
 neuron (Supplementary Table 4 available online at 
http://www.informahealthcare.com/doi/abs/10.3109/
15622975.2011.650204) in all brain regions of each 
group. This of course, might be due to IR expression 
in glia cells in addition to the expression in the neu-
ronal cells. It is known that glia cells can express 
insulin receptors as well (Verdier and Penke 2004). 
In our study we focused on the changes in neuronal 
levels of IR β and did not measure glial alterations. 
Still since it is documented in the literature that in 
AD there is an increase in glial cells (Vehmas et al. 
2003; Ryu et al. 2009; Venneti et al. 2009), it is 
rather less likely that our fi ndings might occur due 
to changes in glial cells. However we cannot exclude 
the possibility whether there can be a  “ selective ” 
neuronal cell lost of only IR β positive neurons in 
AD. Since this is a very interesting question, we will 
investigate this topic further on. 
 Additionally, all patient groups possessed signifi -
cantly more PPAR γ (p) positive cells than the con-
trol group in all investigated brain regions. We were 
interested in PPAR γ (p) because 6 months of treat-
ment with rosiglitazone, a typical T2DM treatment 
and a PPAR γ agonist, preserved cognitive function 
insulin, IGF-1 polypeptide, and related receptor 
genes in the whole brain (Steen et al. 2005). 
 In the current study we examined whether 
patients with T2DM shared common histological 
features with AD, such as fewer IR β positive brain 
cells, and whether this patient group harboured sig-
nifi cantly fewer IR β positive cells in the hippocam-
pus but not in the prefrontal cortex. We were unable 
to confi rm our expectation that patients with AD 
plus T2DM had signifi cantly fewer IR β positive 
cells than the single-disease groups, but these 
patients had signifi cantly fewer IR β positive cells in 
the hippocampus. Thus, it seems that IR β loss in 
the brain is a restricted phenomenon, and cannot 
decrease past a certain level. Interestingly, only the 
hippocampus (not the prefrontal cortex) was 
affected in patients with T2DM plus AD. Condi-
tions caused by insulin abnormalities, such as 
T2DM, are associated with an increased risk of age-
related cognitive decline (Luchsinger et al. 2001; 
Peila et al. 2002), possibly due to the lower num-
bers of IR β positive cells in the hippocampus of 
T2DM patients observed in this study. We also cal-
culated the ratio of IR β positive cells against num-
ber of all detected neurons. This analysis indicates 
 
Figure 5. Schematic representation of components of the system encompassing the insulin receptor (IR) and peroxisome proliferator-
activated receptor (PPAR). Interactions between PPAR, MAPK/PI3K, and the IR pathways occur at various levels and are indicated as 
arrows (activation) or dots (inhibition). P   phosphorylated.   activation; ¾·   inhibition;   transport from nucleus into cytoplasma 
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characteristics and subunit structure. Biochimie 67:
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receptor PPARgamma in Alzheimer’s disease. Curr Alzheimer 
Res 4(2):159 – 164. 
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and Alzheimer’s disease. J Alzheimers Dis 16(4):693 – 704. 
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Diabetes mellitus and risk of Alzheimer’s disease and dementia 
with stroke in a multiethnic cohort. Am J Epidemiol 154:
635–641. 
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Maccioni RB. 2008. Insulin resistance and Alzheimer’s dis-
ease: molecular links & clinical implications. Curr Alzheimer 
Res 5:438–447. 
 Peila R, Rodriguez BL, Launer LJ. 2002. Type 2 diabetes, 
APOE gene, and the risk for dementia and related patholo-
gies: The Honolulu-Asia Aging Study. Diabetes 51:
1256–1262. 
 Qiu C, De Ronchi D, Fratiglioni L. 2007. The epidemiology 
of the dementias: an update. Curr Opin Psychiatry 20:
380–385. 
 Qiu WQ, Folstein MF. 2006. Insulin, insulin-degrading enzyme 
and amyloid-beta peptide in Alzheimer’s disease: review and 
hypothesis. Neurobiol Aging 27(2):190 – 198. 
 Ryu JK, Cho T, Choi HB, Wang YT, McLarnon JG. 2009. Micro-
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component in Alzheimer’s disease pathology. J Neurosci 29:
3–13. 
 Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. 
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Alzheimer disease. Neurobiol Aging 32(9):1626–33. 
 Sims-Robinson C, Kim B, Rosko A, Feldman EL. 2010. How does 
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6:551–559. 
for patients with AD and amnestic mild cognitive 
impairment compared with a placebo-treated group 
(Watson et al. 2005). A number of studies have 
examined potential mechanisms by which PPAR γ 
agonists may ameliorate AD pathogenesis and pro-
gression (Landreth 2007; Neumann et al. 2008); 
PPAR γ agonists improve insulin sensitivity by 
decreasing the level of circulating insulin, increas-
ing insulin-mediated glucose uptake, and enhanc-
ing insulin action in the brain, resulting in cognitive 
improvement (Sato et al. 2011). The phosphory-
lated isoform of PPAR γ is the inactive variant of this 
protein (Figure 5) (Adams et al. 1997), and there-
fore it was not surprising to observe higher num-
bers of PPAR γ (p) positive cells in the brains of all 
patient groups compared to the control group. 
However, we were unable to detect between-patient 
group differences, suggesting that PPAR γ (p) is 
equally affected in AD and T2DM and may be why 
the PPAR γ agonist had positive effects in AD 
patients as well as in T2DM patients. In our par-
ticular study, we focused on the phosphorylated 
form of PPAR γ , which seems to play the important 
role in the pathophysiology of T2DM and maybe 
also in AD, but further investigations about the 
ration between phophorylated and non-phosphory-
lated PPAR γ will be necessary and will be done in 
our laboratory. 
 In conclusion, T2DM and AD may not be directly 
linked, but may share common histological features 
including lower numbers of IR β positive cells in the 
hippocampus and higher numbers of PPAR γ (p) pos-
itive cells in the prefrontal cortex and the hippocam-
pus. These observations may at least partially explain 
the increased frequency of AD in elderly diabetic 
patients. 
 Acknowledgements 
 The authors express their thanks for post-mortem 
brain tissue samples provided by BrainNet Europe 
II. We also add a special thank you to Mrs Michaela 
Hartmann and Mrs Hannelore Schraut for their 
excellent technical work and help. 
 Statement of Interest 
 None to declare. 
 References 
 Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK. 1997. 
Transcriptional activation by peroxisome proliferator-activated 
receptor gamma is inhibited by phosphorylation at a consensus 
mitogen-activated protein kinase site. J Biol Chem 272:5128–
5132. 
8  J. Bartl et al. 
 Supplementary material available online 
 Supplementary Tables 1–4 to be found available 
online at http://www.informahealthcare.com/doi/abs/
10.3109/15622975.2011.650204.  
 Verdier Y, Penke B. 2004. Binding sites of amyloid beta-peptide 
in cell plasma membrane and implications for Alzheimer’s 
disease. Curr Protein Pept Sci 5(1):19 – 31. 
 Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, 
Asthana S, et al. 2005. Preserved cognition in patients with 
early Alzheimer disease and amnestic mild cognitive impair-
ment during treatment with rosiglitazone: a preliminary 
study. Am J Geriatr Psychiatry 13:950–958. 
 Watson GS, Craft S. 2003. The role of insulin resistance in the 
pathogenesis of Alzheimer’s disease: implications for treatment. 
CNS Drugs 17(1):27 – 45. 
 Watson GS, Craft S. 2004. Modulation of memory by insulin and 
glucose: neuropsychological observations in Alzheimer’s dis-
ease. Eur J Pharmacol 490(1 – 3):97 – 113. 
 Xu W, Qiu C, Winblad B, Fratiglioni L. 2007. The effect of 
borderline diabetes on the risk of dementia and Alzheimer’s 
disease. Diabetes 56:211–216. 
 Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, 
et al. 2005. Impaired insulin and insulin-like growth factor 
expression and signaling mechanisms in Alzheimer’s disease--is 
this type 3 diabetes? J Alzheimers Dis 7:63–80. 
 Strachan MW, Deary IJ, Ewing FM, Frier BM. 1997. Is type II dia-
betes associated with an increased risk of cognitive dysfunction? A 
critical review of published studies. Diabetes Care 20:438–445. 
 Umegaki H. 2009. Pathophysiology of cognitive dysfunction in 
older people with type 2 diabetes: vascular changes or neuro-
degeneration? Age Ageing 39(1):8 – 10. 
Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. 2003. 
Immune reactive cells in senile plaques and cognitive decline 
in Alzheimer’s disease. Neurobiol Aging 24:321–331 . 
 Venneti S, Lopresti BJ, Wang G, Hamilton RL, Mathis CA, 
Klunk WE, et al. 2009. PK11195 labels activated microglia 
in Alzheimer’s disease and in vivo in a mouse model using 
PET. Neurobiol Aging 30:1217–1226. 
        1
 Supplementary Table 1: Demographic data of postmortem brains; AD   Alzheimer’s disease; T2DM   type 2 diabetes mellitus; 
m   male; f   female; SEM   standard error of mea n  
Control AD AD   T2DM T2DM
Age, years
 [mean (  /SEM)] 
69 (  /9) 75 (  /7) 75 (  /6) 71 (  /6)
 Gender (m/w)
4/5 5/5 6/4 4/6
 Braak
0-I IV-VI III-V 0-I
 Supplementary Table 2: Gender differences in insulin receptor (IR)  ß positive cells and peroxisome proliferatoractivated receptor γ 
(PPAR γ ) phosphorylated (p) in postmortem human brain. 
Region Diagnose gender PPAR γ (p) MW(%) IR β MW(%)
Cortex Control m 49.89 (  /3.31) 50.34 (  /6.75)
f 49.07 (  /2.61) 47.26 (  /2.94)
AD m 72.73 (  /6.29)  33.15 (  /2.03) 
f 78.8 (  /4.43)  18.76 (  /1.82)
[p    0.0003] 
T2DM m 81.91 (  /3.34) 52.37 (  /8.36)
f 74.56(  /1.95) 56.75 (  /4.15)
AD   T2DM m 77.6(  /4.36) 51.01 (  /3.75)
f 76.36 (  /1.94) 41.91 (  /3.78)
dorsal Hippocampus Control m  58.37 (  /2.43) 46.65 (  /5.73)
f  39.48 (  /4.96)
[p    0.0019] 
46.11 (  /3.71)
AD m 65.530(  /5.97)  36.94 (  /7.06) 
f 78.83 (  /4.10)  20.63 (  /1.55)
[p    0.0038] 
T2DM m  80.56 (  /2.63) 29.57 (  /4.72)
f  69.24 (  /3.03) 
[p    0.0127] 
42.70 (  /15)
AD   T2DM m 83.73 (  /3.31)  29.04 (  /2.63) 
f 79.5(  /2.52)  41.95 (  /3.41)
[p    0.0083] 
ventral Hippocampus Control m 53.31 (  /3.45) 33.40 (  /5.29)
f 43.40 (  /4.80) 47.64 (  /4.51)
AD m  63.0(  /3.65)  28.03 (  /3.85) 
f  81.39 (  /2.179)
 [p    0.0017] 
 17.61 (  /2.06) 
[p    0.0161] 
T2DM m  86.30 (  /2.35) 34.35 (  /2.55)
f  77.23 (  /2.01) 
[p    0.008] 
30.00 (  /3.11)
AD   T2DM m 73.74 (  /5.46) 34.35 (  /2.55)
f 70.80 (  /3.92) 30.00 (  /3.11)
 AD   Alzheimer Disease; T2DM   Diabetes type II; m   male; f   female; MW(%)   mean value of enumerating cells in percent. Statistical 
Analysis was done via ANOVA and followed posthoc scheff é test;  Bold   p    0.05. 
Supplementary material for Bartl J., Monoranu C-M., Wagner A-K., Kolter J., Riederer P. & Grünblatt E. 
Alzheimer’s disease and type 2 diabetes: Two diseases, one common link? Biol Psychiatry, 2012; DOI: 
10.3109/15622975.2011.650204.
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 Supplementary Table 4: Ratio between Insulin receptor (IR)  β 
and amount of neurons in postmortem brains; AD   Alzheimer 
disease; T2DM   type 2 diabetes mellitus. 
 Region  Group 
 Ratio 
 (IR β positive cells/
amount of neurons)
prefrontal Cortex Control 1.47
AD 1.14
AD   T2DM 1.58
T2DM 1.86
dorsal Hippocampus Control 1.85
AD 1.38
AD   T2DM 1.29
T2DM 1.05
ventral Hippocampus Control 2.01
AD 1.24
AD   T2DM 1.35
T2DM 1.88
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Introduction  
Alzheimer´s dementia (AD) is not anymore characterised just by the accumulation and deposition of 
amyloid beta (Aβ) peptides and hyperphosphorylated tau proteins within the brain; in the mean time, it 
is also characterised by synaptic loss (Small, 2004), imbalanced metabolism (Schindowski et al., 2008; 
Grünblatt et al., 2010), abnormal protein cross-linking (Munch et al., 1998; Wang et al., 2008), and 
disturbance of the insulin signalling pathway (Hoyer et al., 1994; de la Monte et al., 2009; Riederer et 
al., 2010). Although more and more factors are found to be involved in AD, excessive Aβ42 deposition 
is still considered to play a major role in AD. However, the mechanisms that contribute to abnormal 
Aβ42 accumulation are not fully understood, both increased production and decreased degradation have 
been observed (Crouch et al., 2008). Aβ42 are able to adopt many differently shaped aggregates 
including amyloid fibrils (Glabe, 2008) as well as nonfibrillar aggregates that are also termed soluble 
Aβ42 “oligomers”(Haass and Selkoe, 2007). It is not well established which Aβ state is most 
responsible for AD or why. Recent evidence strongly implicates Aβ42 oligomers as the proximal 
pathogenic trigger (De Felice et al., 2008). These oligomers are markedly elevated in the brain and 
cerebrospinal fluid of postmortem AD patients and appear to play a critical role in the synaptic failure 
and memory deficits of early AD (Klyubin et al., 2008). It is therefore important to determine directly 
whether neurons exposed to oligomers undergo pathological changes characteristic of AD brain. In the 
current study, we sought to verify the effects of both oligomers and aggregated Aβ42 peptides on gene 
expression, protein level and enzyme activity in vitro. The cell culture model chosen for this 
investigation was the human SH-SY5Y neuroblastoma cell line. These cells show the most common 
neurobiochemical (e.g. enzymes like dopamine β-hydroxylase, acetylcholintransferase, etc. and 
neurotransmitter like dopamine, adrenaline, acetylcholine, GABA) and neurobiological factors (e.g. 
dopamine transporter and receptors, GABAergic receptors, etc.) (Biedler et al., 1978; Ross et al., 
1983) and can be perfectly used as an experimental model to study effects of Aβ42 oligomers and 
aggregated Aβ42 peptides. Our main focus lay on treatment effects on -secretase (BACE), glycogen 
synthase kinase 3α (GSK3α), glycogen synthase kinase 3 (GSK3), phosphatidylinisitol-3 kinase 
(PI-3K), insulin degrading enzyme (IDE), insulin receptor substrate 1 (IRS1), insulin receptor (INSR) 
and monoamine oxidase B (MAO-B). They are all already known to be involved in the pathology of 
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AD: BACE is the first protease in the processing of amyloid precursor protein (APP) leading to the 
production of Aβ42 in the brain, therefore it is one recent target for therapeutic treatment of AD (Ghosh 
et al., 2011). Over-activity of GSK3 accounts for memory impairment, tau hyperphosphorylation, 
increased A production and local plaque-associated microglial-mediated inflammatory responses; all 
of which are hallmark characteristics of AD (reviewed in (Hooper et al., 2008)). PI-3K has been 
identified as second messenger system providing anti-apoptotic signal to various cell types (Brunet et 
al., 2001). Additionally, neuroprotection against extracellular Aβ42 toxicity is dependent on PI-3K 
pathway (Zhang et al., 2003; Lesne et al., 2005). IDE is a metalloprotease that apart from insulin also 
binds and degrades other substrates, including Aβ42, therefore reduced IDE activity diminishes Aβ 
clearance and contributes to the formation of senile plaques (Mukherjee et al., 2000). Not only for IDE 
insulin and Aβ42 are counterparts, in fact Aβ42 peptides directly compete with insulin for binding to the 
INSR (de la Monte et al., 2009) and INSR dysfunction impairs cellular clearance of neurotoxic 
oligomeric Aβ42 (Zhao et al., 2009). MAO-B activity is significantly increased in AD patients (Gotz et 
al., 1998; Grünblatt et al., 2005) and inhibition of MAO-B has a neuroprotective effects for AD 
(reviewed in (Riederer et al., 2004). 
Material and Methods 
Cell culture  
SH-SY5Y cells were bought from European Collection of Cell Cultures and grown in buffered 
Dulbecco`s modified Eagle medium (DMEM/F-12) (Pan Biotech GmbH, Aidenbach, Germany) 
supplemented with 10% fetal bovine serum  and 0.1% gentamycin (50 mg/ml) (Life technologies, 
Darmstadt, Germany) in a humidified incubator (5% CO2) at 37°C.  
Preparation of soluble and aggregated Aβ42 
The preparation of the Aβ42 peptide was modified according to Dahlgren (Dahlgren et al., 2002). 
500mg of freeze-dried Aβ42 (Millipore, Schwalbach, Germany) was dissolved in 1,1,1,3,3,3 
hexafluoroisopropanol (HFIP) to a concentration of 1mM and incubated for one hour at room 
temperature. Subsequently, the HFIP was removed by using a vacuum centrifuge and the peptide film 
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was dissolved in dry dimethyl sulfoxide (DMSO) to a final concentration of 5mM. For aggregated 
Aβ42 peptides, the solution was diluted with 10mM HCl and stored for 7 days in the incubator at 37°C. 
The test concentrations of both the soluble and the aggregated Aβ42 were finally diluted with normal 
cell culture medium. 
Cell treatment with Aβ42 
For western blot (WB), enzyme linked immunosorbent assay (ELISA), fluorescent ELISA and 
quantitative real-time polymerase chain reaction (QRT-PCR) , SH-SY5Y cells were treated with 
varying concentrations of soluble and aggregated Aβ42 (see preparation above) (0, 5, 1, 2,5 and 10µM), 
or purified DMSO or HCl as a control, by adding it in the right concentration to the culture medium. 
The reaction was stopped after 48 h and cells were trypsinized for further investigations. 
Cytotoxicity  
To determine a possible toxic effect of Aβ42 on the cells, the CytoTox-Glo
TM
 test from Promega 
(Mannheim, Germany) was performed. For testing the cytotoxicity effect, 10.000cells/ml  per well 
were cultivated for 24 hours at 37°C in 5% CO2 saturation in the incubator, so that the cells could 
adhere to the bottom of the wells. Afterwards cells were treated with soluble or aggregated Aβ42 in a 
concentration of 0.1, 0.5, 1, 2, 3, 5, 10, 20, 50 and 100 µM. Reaction was measured 48h later. 
RNA extraction and QRT-PCR 
Total RNA was extracted from SH-SY5Y cells using the RNeasy Plus MiniKit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Total RNA (500 ng) was reverse transcribed 
using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Munich, Germany). QRT-PCR was 
performed using an iCycler iQ
TM
 Real Time PCR Detection System (Bio-Rad) and the SYBR-Green 
detection method. The QRT-PCR reaction was optimized according to the manufacturer’s instructions. 
QuantiTech Primer assays for -actin (ACTB; QT00193473), glyceraldehyde-3-phosphate dehdroge-
nase (GAPDH, QT01192646), ribosomal protein L13A (RPL13A; QT00089915), peptidylprolyl 
isomerase A (PPIA, QT01866137), -secretase (BACE, QT00084777), glycogen synthase kinase 3α 
(GSK3α, QT00075306), glycogen synthase kinase 3 (GSK3ß, QT00057134), phosphatidylinisitol-3 
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kinase (PI-3K,  QT00035175), insulin degrading enzyme (IDE, QT00080773), insulin receptor 
substrate 1 (IRS1, QT00074144) and  insulin receptor (INSR, QT00082810) were purchased from 
Qiagen (Hilden, Germany). ACTB, GAPDH, RPL13A and PPIA were used for normalization 
according to GeNorm (Vandesompele et al., 2002). The amplified transcripts were quantified using the 
comparative threshold cycle (Ct) analyzed using the BioRad iCycler iQ program.  
Western blot  
Western blotting was used to detect changes in the protein levels of Insulin receptor (IR) β subunit in 
SH-SY5Y cells. To determine total protein amount of each sample, Bradford protein assay was 
conducted (Sigma-Aldrich, Schorndorf, Germany). Samples (50µg of total protein, denaturated with 
dithiothreitol) were separated on 4-12% Bis-Tris gel and transferred onto nitrocellulose membranes 
(Life technologies, Darmstadt, Germany). Protein of interest was detected using its specific antibodies: 
rabbit anti-IRβ (antibody) (1:250, Santa Cruz, Heidelberg, Germany). Following blocking the 
membrane for one hour at room temperature (5% blocking milk in TBS-Tween) and afterwards 
incubation with primary antibody at 4°C overnight, membranes were incubated with HRP conjugated 
secondary antibody (1:15.000, Sigma-Aldrich, Schorndorf, Germany) for one hour at room 
temperature. The IRβ protein immunoreactive bands were detected using the enhanced 
chemiluminescence (ECL) detection plus system from GE Healthcare (Freiburg, Germany) and 
quantified using ImageJ software without modifying picture properties (e.g. gain, colour or contrast). 
For comparison the values of β-actin, as a house keeping protein, were used. The membranes were 
stripped to remove the attached antibodies. It was followed by one-hour incubation in 5% BSA 
blocking solution at room temperature. The murine β-actin antibody (1:5000, Santa Cruz, Heidelberg, 
Germany) was already linked with HRP and was detected and quantified like IRβ protein.  
Enyzme linked immunosorbent assays 
The Invitrogen (Darmstadt, Germany) GSK-3β kit is a solid phase sandwich enzyme linked 
immunosorbent assay (ELISA) and was used to detect and quantify the level of total GSK-3β protein 
and of GSK-3β protein phosphorylated at serine residue 9. Samples were prepared according to 
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manual. Detected protein amount was normalized with total protein amount of used samples, as 
detected via Bradford protein assay (Sigma-Aldrich, Schorndorf, Germany). 
Enzyme activity 
MAO-B enzyme activity was measured by using amplex red monoamine oxidase assay kit (Life 
technologies, Darmstadt, Germany). 50µg of total protein (detected via Bradford protein assay) of 
homogenized SH-SY5Y cells was diluted in reaction buffer and varying concentrations of soluble and 
aggregated Aβ42 (see preparation above) (0.5, 1, 2.5 and 10µM) were added. After 30 minutes 
incubation at 37 °C, 100μl substrate mix was added and again incubated for 1 hour at 37°C. The 
endpoint measurement was done in a fluorescence multi plates meter (Novostar) at an excitation of 
542 nm and an emission of 590 nm. 
Statistical analysis 
Statistical analyses of the WB, ELISA and QRT-PCR data were performed using StatView for 
Windows (SAS Institute Inc., version 5). Statistical tests included analysis of variance (ANOVA) with 
post-hoc Scheffé Test. Significance was set as p<0.05. For a better comparison of the data, we 
normalized the results and converted the data into percentages. The control group was set as 100%. 
The results represent at least 3 repeated experiments with around 4 internal repeats. 
Results 
Soluble and aggregated species of Aβ42 were prepared as described above and controlled via electron 
microscopy (shown in supplementary figure 1). Avoiding neural cell death, we tested a wide range of 
Aβ42 µM doses (0-100µM) before cell treatment and used just the nontoxic range from 0-10µM for 
this study. Concentration of over 20M aggregated A42 showed significant cell toxicity, while for 
soluble form only a trend to toxicity was observed (supplementary figure 2). 
Gene expression  
BACE, GSK3α, GSK3β, PI-3K, IDE, IRS-1 and INSR were the investigated genes. After gene 
expression analysis we could detect two genes with significant differences between treated and 
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untreated cells. GSK3β was significantly up-regulated after cell treatment with 1 and 2µM (+362% 
p<0.05; +357 p<0.05) of soluble Aβ42 and we could detect a tendency of higher gene expression after 
treatment with 1, 2, 5 and 10µm of the aggregated Aβ42 (Table 1). The second gene revealing 
statistically significant results was the INSR. Treatment with 5 and 10µM of soluble peptides tended to 
result in a lower INSR gene expression compared to untreated cells while on the other hand, treatments 
with 1µM of the aggregated peptides tended to result in a higher expression and treatment with 5 and 
10µM even led to a significant overexpression of INSR (+183 p<0.05; +201 p<0.05; Table 1). Based 
on these results we further investigated the protein expression of these two genes in order to examine 
whether the differences influence gene transcription. 
Protein level  
After SH-SY5Y cells were treated with all doses of soluble Aβ42, significantly more GSK3β protein 
levels (30-45%) was detectable compared to the control cells (p<0.01, figure 1a), which confirm the 
gene expression data of GSK3β. Treatments with aggregated peptides did not show any significant 
effects on GSK3 total protein levels in non of the used doses (figure 1A). Because GSK3β is a kinase 
enzyme, that when phosphorylated at serine residue 9 becomes inactive, we investigated the 
phosphorylated form of this protein to affirm whether it is more or less active after Aβ42 treatment to 
the cells. We calculated the ratio between total amount of GSK3 protein and its phosphorylated form, 
which represents the enzyme activity (figure 1B). Remarkably, not only the total protein amount of 
GSK3β was statistically significantly increased after treatment with soluble peptides, but there was 
also a significant detectable enhancement of the enzyme activity under this condition (145%-231% 
more activity in all used dosages compared to untreated cells; 0.01<p<0.05; figure 1B). On the other 
hand the enzyme activity did not alter after treatment with aggregated peptides (figure 1B).  
The gene expression data of INSR demonstrated already a tendency for reduced expression after 
treatment with soluble peptides (table 1), which resulted in significantly decreased total amount of IR 
after treatment with 0.5, 1 and 2µM of soluble Aβ42 (50%-60% less total IR protein amount 
compared to untreated cells, p<0.05; figure 2). On the other hand, in the gene expression analysis a 
significant overexpresion of INSR after treatment with aggregated peptides was observed (table 1), 
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which was confirmed only at 1µM aggregated peptide treatment for the total IR protein expression. 
At 1µM of aggregated Aβ42 we could detect 60% more IR compared to control cells (p<0.05; figure 
2).  
Enzyme activity 
MAO B enzyme activity was significantly reduced after cell homogenate treatment with 1, 2, 5 and 
10µM of soluble Aβ42 peptides (18%-30% less activity, p<0.01; figure 3). In contrast the aggregated 
peptides enhanced the enzyme activity with significant results at 1, 2 and 5µM of aggregated peptide 
(30%-40% more activity compared to control; p<0.01; figure 3).  
Discussion 
AD is one of the most common form of dementia in the elderly (Blennow et al., 2006) and although 
increasing factors are found to be involved in AD, excessive Aβ42 deposition is still considered to play 
a major role in this disease. Aβ42 is derived from the APP by the action of two aspartyl proteases, β- 
and γ-secretases. So accrued Aβ42 molecules tend to aggregate to form  soluble oligomers, protofibrils, 
and β-amyloid fibrils, which have been suggested to cause neuronal dysfunction in the brains of AD 
patients (reviewed in (Ono and Yamada, 2011)). However, it is not well established which Aβ42 state 
is most responsible for AD or why. In this study we verified, which effects Aβ42 oligomers and 
aggregated Aβ42 peptides have on gene expression, protein level and enzyme activity of the insulin  
and APP pathways in vitro. In particular, we have observed a strong influence of the soluble form of 
Aβ42 peptides on GSK3β gene expression as well as on its protein level and activity. It has been 
already postulated that GSK3β activity might exert a central role in the development of AD (Hooper et 
al., 2008). GSK3β activity was implicated in tau phosphorylation, APP processing, Aβ42 production 
and neurodegeneration (Balaraman et al., 2006; Hooper et al., 2008). Our finding of increased GSK3β 
gene/protein expression and activity points to the fact, that GSK3 might be a crucial element in the 
Aβ42-triggered molecular cascade leading to potential neurodegeneration. The observed effect of Aβ42 
oligomers on GSK3β might be mediated by interaction with different receptors, but mainly with the 
interaction of INSR. It was already shown that Aβ42 oligomers interact with neuronal INSR to cause 
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impairments of the receptor expression and function (Townsend et al., 2007; Zhao et al., 2009). 
Normally, activation of INSR leads to the phosphorylation of PI 3-kinase, which leads to an activation 
of AKT. Once active, AKT enters the cytoplasm where it leads to the phosphorylation and inactivation 
of GSK3 (Jolivalt et al., 2008). Thus, although normal INSR activity helps to defend against the 
accumulation of toxic Aβ42 oligomers, the INSR themselves are vulnerable to oligomer-initiated 
dysfunction. The presented data indicate the fact that this relationship has the potential to generate an 
insidious pathogenic loop. We could observe a significant reduction of INSR gene and protein 
expression after SH-SY5Y treatment with soluble Aβ42 oligomers compared to untreated cells. 
Consistent with the actual finding reported here, our group could already report that in AD patient less 
INSR were found especially in the hippocampal region of the brain (Bartl et al., 2012). Not only an 
impairment of INSR leads to an activation of GSK3β as explained before, also oxidative stress can 
enhance the activity of this kinase (Hernandez and Avila, 2008). In 2004, Riederer et al. already 
reviewed the link between oxidative stress and AD, especially regarding the increased MAO-B 
activity (Riederer et al., 2004). MAO-B is a flavin containing enzyme localized in the outer 
mitochondrial membrane and is responsible for the oxidative deamination of neurotransmitters 
(noradrenaline, dopamine and serotonin) and exogenous amines. During its catalytic activity it 
produces hydrogen peroxide formed in the reaction, which is a possible source for oxidative stress. 
Highlighting more the possible link between Aβ42, GSK3 and MAO-B we analyzed the effect of 
soluble and aggregated peptides on MAO-B enzyme activity. Interestingly, the soluble oligomers 
inhibited the enzyme activity significantly, but the aggregated forms of Aβ42 peptides, which are more 
similar to the amyloid plaques within the brain, enhanced the MAO-B activity in a dose dependent 
manner. Although we could find an inhibition of MAO-B activity after soluble peptide treatment, it 
cannot be concluded that these oligomers might be neuroprotective. An increased MAO-B activity was 
found in senile plaques (Saura et al., 1997) and in platelets of AD patients (Gotz et al., 1998), 
therefore our results of enhanced MAO-B activity following treatment with aggregated while not with 
soluble Aβ42 peptides, might indicate the involvement of the fibrillar structures of Aβ42 in the oxidative 
stress cascade known to play an important role in AD (Grünblatt et al., 2005; Grünblatt et al., 2010). 
To our knowledge, this is the first report indicating the direct influence of soluble or aggregated 
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peptides on MAO-B activity in vitro. Our data affirm that there has to be a neurobiochemical link 
between MAO-B and Aβ42. In conclusion, our results suggest that Aβ42 oligomers seem to be more 
involved in cellular mechanisms linked to AD, except in enhancement of MAO-B activity, than the 
aggregated Aβ42 peptides, which is confirmed with the actual literature. AD seem to involve numerous 
mechanisms such as amyloid plaque formation, tau hyperphoshprylation, apoptosis, impairment of 
insulin signaling pathway and oxidative stress, causing neurodegeneration, which means that further 
investigations are necessary to enlighten the molecular mechanism of AD pathogenesis. 
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Table 1:  Gene expression data after SH-SY5Y treatment with soluble and aggregated Aβ42 
peptides. 
  
soluble Aβ42 (µM)  
[mean value (%) 
± standard derivate(%)] 
aggregated Aβ42 (µM)  
[mean value(%) 
 ± standard derivate(%)] 
Gene 
                   Doses 
0.5 1 2 5 10 0.5 1 2 5 10 
BACE 
97 
±20 
88 
±19 
96  
±19 
105 
±21 
103 
±22 
182 
±88 
129 
±37 
247 
±153 
108 
±47 
161 
±57 
GSK3α 
98 
±26 
79 
±20 
88 
±19 
69 
±13 
97 
±19 
96 
±12 
97 
±9 
105 
±12 
110 
±15 
115 
±14 
GSK3β 
149 
±37 
462 
±160 
457 
±206 
264 
±85 
220 
±57 
83 
±11 
337 
±88 
379 
±91 
286 
±57 
335 
±74 
PI-3K 
148 
±59 
145 
±40 
97 
±25 
86 
±20 
100 
±24 
114 
±43 
119 
±39 
101 
±29 
120 
±39 
111 
±28 
IDE 
89 
±60 
81 
±52 
58 
±39 
83 
±59 
80 
±55 
77 
±24 
90 
±31 
91 
±32 
71 
±21 
115 
±41 
IRS-1 
36 
±99 
79 
±41 
65 
±21 
97 
±43 
129 
±62 
54 
±18 
114 
±57 
57 
±13 
52 
±18 
52 
±18 
INSR 
101 
±17 
70 
±11 
90 
±5 
75 
±7 
76 
±14 
197 
±71 
195 
±45 
154 
±49 
283 
±46 
301 
±40 
 
Shown is the percentage of the mean values of gene expression of -secretase (BACE), 
glycogen synthase kinase 3α (GSK3α), glycogen synthase kinase 3 (GSK3), 
phosphatidylinisitol-3 kinase (PI-3K), insulin degrading enzyme (IDE), insulin receptor 
substrate 1 (IRS1), insulin receptor (INSR) and monoamine oxidase B (MAO-B).measured by 
real time PCR. Reference value (100%) is control group with untreated SH-SY5Y cells. For 
the statistical analysis ANOVA, post-hoc Scheffé with a specified significance level of p 
<0.05 was used. BOLD= 0.05 < p <0.01, italic = 0.1 < p <0.05 versus control. 
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Figure 1: Total protein amount of glycogen synthase kinase 3β (GSK3β) and ratio of 
phosphorylated GSK3ß / total GSK3ß after SH-SY5Y treatment with soluble and aggregated 
Aβ42 peptides. A Shown is the percentage of the mean values of total amount of the protein measured 
by a sandwich ELISA. B Shown is the percentage of the mean values of total amount of the protein 
and of phosphorylated protein amount measured by a sandwich ELISA. Reference value (100%) is 
control group with untreated SH-SY5Y cells. For the statistical analysis ANOVA, post-hoc Scheffé 
with a specified significance level of p <0.05 was used. *= p <0.05, ** = p <0.01 versus control. The 
sample size was n = 6-12.  
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Figure 2: Total protein amount of insulin receptor (INSR) after SH-SY5Y treatment with soluble 
and aggregated Aβ42 peptides. Shown is the percentage of the mean values of total amount of the 
protein measured by western blot. Reference value (100%) is control group with untreated SH-SY5Y 
cells. For the statistical analysis ANOVA, post-hoc Scheffé with a specified significance level of p 
<0.05 was used. *= p <0.05, ** = p <0.01 versus control. The sample size was n = 6-12. 
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Figure 3: Monoamino oxidase B (MAO-B) activity after SH-SY5Y treatment with soluble and 
aggregated Aβ42 peptides. Shown is the percentage of the mean values of enzyme activity measured 
by an amplex red monoamine oxidase assay. Reference value (100%) is control group with untreated 
SH-SY5Y cells. For the statistical analysis ANOVA, post-hoc Scheffé with a specified significance 
level of p <0.05 was used. *= p <0.05, ** = p <0.01 versus control. The sample size was n = 20-38. 
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Supplementary Figure 1: Electron microscope pictures of soluble and aggregated Aβ
42
 peptides. 
5µl of samples were spotted on a glow discharged, carbon-coated grid and incubated for 5 min, 
washed with distilled water, fixed with 2.5% glutaraldehyde, stained with a 1% (w/v) aqueous uranyl 
acetate solution, and examined using a transmission electron microscope. 20.000 fold magnification. 
A. arrow points to soluble Aβ
42
 peptides; B. arrow points to aggregated Aβ
42
 peptides. 
 
A B 
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Supplementary figure 2: Cytotoxicity of soluble and aggregated Aβ42 peptides. Shown is the 
percentage of cell viability compared of control group of SH-SY5Y after 48h treatment with soluble or 
aggregated Aβ42 peptides. The number of viable cells is calculated from the substraction of the dead 
cells of the total cell number. Statistical analysis of cytotoxicity was performed using ANOVA post-
hoc Scheffé. ** = p < 0.01 versus control. The sample size was n=13-22. 
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DETAILED METHODS 
MANUSCRIPT I 
Subjects 
Subjects of the present study were from the VITA (Vienna Transdanube Aging) study which 
was described previously in greater detail 
88
. The VITA study investigated the residents of 
two Viennese districts born between May 1925 and June 1926 (i.e., aged 75 years at 
inclusion). Data refer to the total cohort at baseline recruitment of 606 individuals who 
completed physical health check, questionnaires for education, psychosocial activities and 
neuropsychological examination. The 1
st
 follow-up after 30 months was possible for 476 
subjects. Thirty-eight out of the 606 subjects deceased between baseline and the follow-up 
investigation after 30 months, 70 subjects refused to participate in the follow-up investigation 
and 10 subjects were willing only to take part in a telephone-interview. The 2
nd
 follow-up 
after 60 months was possible for 362 subjects. 81 subjects out of the 606 participants at 
baseline deceased between baseline and the 2
nd
 follow-up investigation, 92 subjects refused to 
take part again in the follow-up investigation, 68 subjects were willing only to take part in a 
telephone-interview or a house visit providing only minimal information and in three subjects 
no contact was possible to establish. A diagnosis of AD was established applying the 
NINCDS-ADRDA criteria at all-time points 
89
. Additional information was obtained in all 
cases for relevant serum parameters such as cortisol and glucose level and T2DM was 
diagnosed according to the guide line of the world health organisation. All participants passed 
through a consensus conference with regard to the diagnoses of possible or probable AD. The 
final diagnosis was made by an experienced geronto-psychiatrist. The number of AD cases 
given in the total sample is the sum of all possible and probable cases in the whole cohort 
(Table 2). The VITA study was carried out with the permission of the Ethics Committee of 
the City of Vienna, Austria and each participant gave a written informed consent.  
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Table 2: Demographic information of the Vienna Transdanube Aging (VITA) study cohort. 
examination parameter total sample 
with IDE genotypes 
AD T2DM 
no yes no yes 
baseline 
sex 
male / female 
247 / 359 232 / 321 5 / 13 194 / 281 44 / 53 
APOE ε4 
no / yes 
469 / 124 429 / 116 13 / 4 365 / 103 78 / 17 
BMI 
mean ± SD 
27.1 ± 3.87 27.14 ± 3.81 24.82 ± 3.29 26.93 ± 3.66 27.76 ± 4.42 
1
st
 
follow-up 
sex 
male / female 
193 / 305 150 / 239 35 / 46 147 / 242 42 / 49 
APOE ε4 
no / yes 
383 / 103 310 / 74 52 / 26 298 / 85 72 / 16 
BMI 
mean ± SD 
27.14 ± 3.91 27.32 ± 3.84 26.22 ± 3.95 26.88 ± 3.67 28.18 ± 4.67 
2
nd
 
follow-up 
sex 
male / female 
163 / 267 107 / 181 48 / 60 124 / 207 35 / 45 
APOE ε4 
no / yes 
327 / 93 229 / 56 73 / 33 249 / 78 65 / 13 
BMI 
mean ± SD 
26.75 ± 4.02 27 ± 4.15 25.92 ± 3.55 26.59 ± 3.88 27.14 ± 4.34 
Abbreviations used: AD = Alzheimer‟s disease; BMI = body mass index; SD = standard deviation; T2DM = 
Type 2 diabetes mellitus.Table 2: Demographic information of the VITA study cohort 
 
DNA extraction 
DNA was prepared from 2 ml EDTA-blood by the standard procedure of proteinase K. 2 ml 
blood was mixed with 2 ml of lysis buffer (0.32 M sucrose 10 mM Tris–HCl, pH 7.5, 1% 
Triton x-100, 5 mM MgCl2), vortexed and centrifuged at 13,000 × g for 20 s. The pellet was 
then resuspended in 4 ml PBS and centrifuged at 13,000 × g for another 20 s, followed by 
resuspension in 2 ml buffer with non-ionic detergents and proteinase K (50 mM KCl, 10 mM 
Tris–HCl pH 8.3, 0.1 mg/ml gelatine, 0.45% NP 40, 0.45% Tween 20, 0.3 g/ml proteinase K) 
and incubated at 60°C for 1 h. Consequently the mix was incubated at 95 ◦ C for 10 min to 
denature the proteinase K. Finally the DNA was aliquoted into cryo-Vials (NUNK, Germany) 
and frozen at -70°C till requirement. 
 
IDE genotyping 
The IDE genotypes were determined using TaqMan assay with the real time PCR reaction 
using specific primers from TaqMan single nucleotide polymorphism (SNP) Genotyping 
Assay (Applied Biosystems, Darmstadt, Germany), which uses the 5´ nuclease assay for 
amplifying and detecting specific SNP alleles in purified genomic DNA samples. 
C_22272896_10(IDE2, rs4646953), C_27104906_10 (IDE7, rs2251101) and C_12116624_10 
DETAILED METHODS 
 
84 
 
(IDE9, rs1887922) assays were used for SNP typing. Analysis of the genotypes was 
conducted on the iCycler software with allelic discrimination program (Bio-Rad, Munich, 
Germany). 
 
A1-42 plasma level 
Plasma levels of amyloid were determined by a double-antibody sandwich enzyme-linked 
immunosorbent assay method according to the company protocol (Innogenetics NV, Ghent, 
Belgium). The INNOTEST -amyloid (1–42) allows the specific and reliable measurement of 
A42 peptides in plasma. The detection range is 5–1000 pg/ml. 
 
Statistical analysis 
Prior to association analysis, IDE SNPs were tested for Hardy-Weinberg equilibrium (HWE) 
with a one degree of freedom χ2-test; no significant departures were detected (all p-values > 
0.001). Associations in the different time points were tested with logistic regression when the 
outcome variable was binary (no/yes), or with linear regression when influence on a 
continuous outcome was examined. For longitudinal association analysis, generalized 
estimating equations were used. Genotypic associations were performed using three different 
models: in the additive model, each individual‟s risk allele count entered the regression; the 
dominant model considered the presence of at least one risk allele and in the recessive model, 
a genotypic risk was only present if the individual was homozygous for the risk allele. The 
Akaike Information Criterion (AIC) was used to choose the best model. In single SNP 
analysis the polymorphism‟s minor allele was assumed to be the risk allele. In haplotype 
analysis, each haplotype allele was tested against all other alleles; to account for phase 
uncertainty, each allele‟s posterior probability was incorporated into the model. Haplotypes 
were defined with the expectation-maximization algorithm 
90
. Associations were considered 
to be significant at α=0.05; due to the limited sample size of this study, the reported nominal 
p-values were not adjusted for multiple testing. All analyses were performed in R version 
2.10.0 using the packages geepack and SimHap (all obtained from http://www.r-project.org). 
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MANUSCRIPT II 
Sample preparation 
The brain samples used in this study were supplied by BrainNet Europe. The entire procedure 
was performed in accordance with the Helsinki Declaration in its latest version and with the  
Convention of the Council of Europe on Human Rights and Biomedicine. Clinical diagnosis 
of AD was based on National Institute of Neurological and Communicative Disorders and 
Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) 
criteria and confirmed by neuropathological findings 
91
. Histological samples were obtained 
from the dorsal and ventral hippocampus and from the prefrontal cortex of post-mortem 
brains from four patient groups (Table 3): age-matched control patients without dementia, 
patients with T2DM, AD patients, and patients with AD plus T2DM. In preparation for 
routine neuropathological examination, the brain was divided midsagittally, and one 
hemisphere was immersed in 4.5% p-formaldehyde (Fischer GmbH, Saarbruecken Germany) 
for 3-4 weeks.  
 
Table 3: Demographic data of postmortem brains 
Abbrevation used: AD= Alzheimer disease; T2DM= type 2 diabetes mellitus; m = male; f = female; SEM = 
standard error of mean 
 
 
Immunohistochemistry  
Paraffin sections (8 µm) of post-mortem brain tissue from the four patient groups were 
deparaffined with an alcohol dilution series. The slides were then boiled in 10 mM 
Citratbuffer cointaing 10.51 g citratmonohydrate and 2 g sodium hydroxide pellets in 5l 
double distillate water (pH 6) for at least 10 min for antigen retrieval. The sections were 
washed three times in Tris-buffered saline, and non-specific binding was blocked with 
blocking solution (BS) containing 10% normal goat serum, 2% bovine serum albumin, and 
0.01% Triton-X 100 in Tris-buffered saline for 1 h at room temperature before incubation 
Table 3: Demographic data of postmortem 
brains 
 Control AD AD+T2DM T2DM 
Age, years 
[mean(+/- SEM)] 
69 (+/- 9) 75 (+/-7) 75 (+/- 6) 71 (+/- 6) 
Gender (m/w) 4/5 5/5 6/4 4/6 
Braak 0-I IV-VI III-V 0-I 
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with the various primary antibodies diluted in BS. The primary antibodies targeted the 
following proteins: IRß (Santa Cruz, Heidelberg, Germany), diluted 1:200; neuronal specific 
enolase (NSE; Abcam, Cambridge, UK), diluted 1:300; and PPARγ(p) (Abcam, Cambridge, 
UK), diluted 1:200 and all antibodies were incubated overnight at 4 °C. The primary 
antibodies were visualised with antibodies conjugated to Alexa® Fluor-488 (green) and 
Fluor-555 (red; Invitrogen, Darmstadt, Germany). All secondary antibodies were incubated 
for 2 h at room temperature in the dark. Finally, the sections were mounted on glass slides and 
cover slipped under Vectashield (Vector Labs, Eiching, Germany) for fluorescence 
microscopy.  
 
Automated cell counting 
Five images of each brain region from each patient were recorded and analysed with Cell^P 
(version 2.0; Olympus, Hamburg, Germany). We used Imaging C within Cell^P to use a 
macro recorder, to define special regions of interest for each investigated protein, and to 
perform automated cell counting. The total cell number for each image was determined, and 
we separately obtained counts for the special regions of interest for each image. Automated 
cell counting helped us maintain the standard error of measurement at the same level for 
image analyses. 
 
Statistical analysis 
Immunohistochemistry images were analysed for the numbers of cells positive for NSE, IRβ, 
and PPARγ(p) staining in comparison to the total number of cells via analysis of variance 
(ANOVA) and a post-hoc Scheffé test with a significance level of p<0.05. Reported values 
were calculated in relative to control levels (100%). The statistical program Stat View 5.0 
(SAS Institute Inc. Cary, NC, USA) was used for all analyses. 
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MANUSCRIPT III 
Cell culture  
SH-SY5Y cells were bought from European Collection of Cell Cultures and grown in 
buffered Dulbecco`s modified Eagle medium (DMEM/F-12) (Pan Biotech GmbH, Aidenbach, 
Germany) supplemented with 10% fetal bovine serum and 0.1% gentamycin (50 mg/ml) (Life 
technologies, Darmstadt, Germany) in a humidified incubator (5% CO2) at 37°C.  
 
Preparation of soluble and aggregated Aβ42 
The preparation of the Aβ42 peptide was modified according to Dahlgren 
92
. 500mg of freeze-
dried Aβ42 (Millipore, Schwalbach, Germany) was dissolved in 1,1,1,3,3,3 
hexafluoroisopropanol (HFIP) to a concentration of 1mM and incubated for one hour at room 
temperature. Subsequently, the HFIP was removed by using a vacuum centrifuge and the 
peptide film was dissolved in dry dimethyl sulfoxide (DMSO) to a final concentration of 
5mM. For aggregated Aβ42 peptides, the solution was diluted with 10mM HCl and stored for 7 
days in the incubator at 37°C. The test concentrations of both the soluble and the aggregated 
Aβ42 were finally diluted with normal cell culture medium. 
 
Cell treatment with Aβ42 
For western blot (WB), enzyme linked immunosorbent assay (ELISA), fluorescent ELISA 
and quantitative real-time polymerase chain reaction (QRT-PCR), SH-SY5Y cells were 
treated with varying concentrations of soluble and aggregated Aβ42 (see preparation above) (0, 
5, 1, 2,5 and 10µM), or purified DMSO or hydrochlorid acid (HCl) as a control, by adding it 
in the right concentration to the culture medium. The reaction was stopped after 48 h and cells 
were trypsinized for further investigations. 
 
Cytotoxicity  
To determine a possible toxic effect of Aβ42 on the cells, the CytoTox-Glo
TM
 test from 
Promega (Mannheim, Germany) was performed. For testing the cytotoxicity effect, 
10.000cells/ml per well were cultivated for 24 hours at 37°C in 5% CO2 saturation in the 
incubator, so that the cells could adhere to the bottom of the wells. Afterwards cells were 
treated with soluble or aggregated Aβ42 in a concentration of 0.1, 0.5, 1, 2, 3, 5, 10, 20, 50 and 
100 µM. Reaction was measured 48h later. 
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RNA extraction and QRT-PCR 
Total RNA was extracted from SH-SY5Y cells using the RNeasy Plus MiniKit (Qiagen, 
Hilden, Germany) according to the manufacturer‟s instructions. Total RNA (500 ng) was 
reverse transcribed using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Munich, 
Germany). QRT-PCR was performed using an iCycler iQ
TM
 Real Time PCR Detection 
System (Bio-Rad) and the SYBR-Green detection method. The QRT-PCR reaction was 
optimized according to the manufacturer‟s instructions. QuantiTech Primer assays for -actin 
(ACTB; QT00193473), glyceraldehyde-3-phosphate dehydrogenase (GAPDH, QT01192646), 
ribosomal protein L13A (RPL13A; QT00089915), peptidylprolyl isomerase A (PPIA, 
QT01866137), -secretase (BACE, QT00084777), glycogen synthase kinase 3α (GSK3α, 
QT00075306), glycogen synthase kinase 3 (GSK3ß, QT00057134), phosphatidylinisitol-3 
kinase (PI-3K, QT00035175), insulin degrading enzyme (IDE, QT00080773), insulin receptor 
substrate 1 (IRS1, QT00074144) and insulin receptor (INSR, QT00082810) were purchased 
from Qiagen (Hilden, Germany). ACTB, GAPDH, RPL13A and PPIA were used for 
normalization according to GeNorm 
93
. The amplified transcripts were quantified using the 
comparative threshold cycle (Ct) analyzed using the BioRad iCycler iQ program. 
  
Western blot  
Western blotting was used to detect changes in the protein levels of Insulin receptor (IR) β 
subunit in SH-SY5Y cells. To determine total protein amount of each sample, Bradford 
protein assay was conducted (Sigma-Aldrich, Schorndorf, Germany). Samples (50µg of total 
protein, denaturated with dithiothreitol) were separated on 4-12% Bis-Tris gel and transferred 
onto nitrocellulose membranes (Life technologies, Darmstadt, Germany). Protein of interest 
was detected using its specific antibodies: rabbit anti-IRβ (antibody) (1:250, Santa Cruz, 
Heidelberg, Germany). Blocking the membrane for one hour at room temperature (5% 
blocking milk in TBS-Tween) and afterwards incubation with primary antibody at 4°C 
overnight, membranes were incubated with HRP conjugated secondary antibody (1:15.000, 
Sigma-Aldrich, Schorndorf, Germany) for one hour at room temperature. The IRβ protein 
immunoreactive bands were detected using the enhanced chemiluminescence (ECL) detection 
plus system from GE Healthcare (Freiburg, Germany) and quantified using ImageJ software 
without modifying picture properties (e.g. gain, colour or contrast). For comparison the values 
of β-actin, as a house keeping protein, were used. The membranes were stripped to remove 
the attached antibodies. It was followed by one-hour incubation in 5% BSA blocking solution 
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at room temperature. The murine β-actin antibody (1:5000, Santa Cruz, Heidelberg, Germany) 
was already linked with HRP and was detected and quantified like IRβ protein.  
 
Enzyme linked immunosorbent assays 
The Invitrogen (Darmstadt, Germany) GSK-3β kit is a solid phase sandwich enzyme linked 
immunosorbent assay (ELISA) and was used to detect and quantify the level of total GSK-3β 
protein and of GSK-3β protein phosphorylated at serine residue 9. Samples were prepared 
according to manual. Detected protein amount was normalized with total protein amount of 
used samples, as detected via Bradford protein assay (Sigma-Aldrich, Schorndorf, Germany). 
 
Enzyme activity 
MAO-B enzyme activity was measured by using amplex red MAO assay kit (Life 
technologies, Darmstadt, Germany). 50µg of total protein (detected via Bradford protein 
assay) of homogenized SH-SY5Y cells was diluted in reaction buffer and varying 
concentrations of soluble and aggregated Aβ42 (see preparation above) (0.5, 1, 2.5 and 10µM) 
were added. After 30 minutes incubation at 37 °C, 100μl substrate mix was added and again 
incubated for 1 hour at 37°C. The endpoint measurement was done in a fluorescence multi 
plates meter (Novostar) at an excitation of 542 nm and an emission of 590 nm. 
 
Statistical analysis 
Statistical analyses of the WB, ELISA and QRT-PCR data were performed using StatView 
for Windows (SAS Institute Inc., version 5). Statistical tests included analysis of variance 
(ANOVA) with post-hoc Scheffé Test. Significance was set as p<0.05. For a better 
comparison of the data, we normalized the results and converted the data into percentages. 
The control group was set as 100%. The results represent at least 3 repeated experiments with 
around 4 internal repeats. 
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DISCUSSION 
GENERAL DISCUSSION 
AD is the most frequent form of dementia in the elderly with an increasing incidence in the 
aging population in industrialized countries in the next decades. Thus, the investigation of 
associations between risk factors, possible genetic candidate genes and influences of other 
disease like T2DM on AD, is of major interest. Several studies have reported a high risk of 
AD in patients with T2DM 
94-98
. Also accumulating evidence supports the hypothesis that AD 
and T2DM share a common link 
79,99,100
; while aging is clearly the strongest risk factor for 
AD, emerging data suggest that T2DM and dyslipidaemic states can contribute substantially 
to AD pathogenesis either directly or as cofactors 
101
. In addition, the co-morbid hypertension 
and overweight of T2DM were found to be linked to risk of dementia 
58,102-104
. The presented 
thesis investigates the questions are there common genetic, histopatholigical and/or proteomic 
features or pathways of AD and T2DM? Summarizing the results of Manuscripts I, II and III 
leads to the conclusion that even though AD and T2DM are sharing common features like low 
density of IRβ and higher density of PPARγ (p) (see results Manuscript II) or Aβ42 influences 
insulin signaling proteins (see results Manuscript III), the risk effects were more independent 
rather than linked, which confirms the term for AD as a Type III Diabetes. In the following 
chapters, this hypothesis will be further discussed: 
Insulin degrading enzyme gene- a link of Alzheimer’s disease with type 2 diabetes mellitus? 
Search for candidate genes and/or analysis of SNP polymorphisms are getting more and more 
attention in the scientific community to find a possibility for earlier treatment and better 
prognosis of symptomatically indistinct illnesses. The presented study laid the main focus on 
IDE as potential link between AD and T2DM (Manuscript I). IDE has obtained much 
attention as a LOAD candidate gene because of its location near to LOAD linkage peaks. The 
IDE gene is located on chromosome 10q23.33, very near a „suggestive‟ linkage peak 
(chromosome 10q24) found several genome-wide linkage studies of LOAD families. 
reviewed in 
105
. Since IDE is also well-known to be associated with increased risk for T2DM 
69,70,106
, the present study aimed at examining the effects of selected common IDE 
polymorphisms on both disease outcomes as well as on the plasma A42 level (see Manuscript 
I). Assuring that the analysed polymorphisms capture the common allelic variation in the up- 
and downstream region, as well as in the gene body of IDE, SNP of IDE2 (upstream), IDE7 
(downstream) and IDE9 (gene body) was further investigated. Subjects of the present study 
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were from the VITA study (see detailed methods Manuscript I). While there was no 
association detectable of IDE9 with neither AD nor T2DM susceptibility, the presented study 
could show that allelic variation at opposing ends of IDE is associated with different 
outcomes: the upstream and 5‟-untranslated region (UTR) harbors polymorphisms (IDE2) 
modifying the AD disease risk and the A42 plasma level, whereas 3‟-UTR and downstream 
variants (IDE7) trigger T2DM susceptibility. In details the minor C allele of IDE2 had a 
protective effect with an OR =0.55 for AD and for the minor G allele of IDE7 bears a 
significant genotypic risk to develop T2DM, with an initial OR of 2.43 (see results 
Manuscript I). The possible protective effect of IDE2 is not easy to explain. 2009 Zuo and 
colleagues 
66
 could demonstrate that variants of polymorphism inside the IDE upstream 
region influences the expression of IDE in an enhanced but also in an inhibited manner. In 
addition previous studies of IDE expression in AD brain tissue have produced inconsistent 
results (reviewed in 
107
). Although increased intracellular and neuronal immunostaining have 
been reported in AD brains, decreased levels of a carboxyl-terminal fragment of IDE were 
detected in cytosolic fractions of AD brains by Western blot analysis. Additionally IDE 
protein levels measured by enzyme linked immunosorbent assay were reported to be 
increased in the cortical microvessels of AD patients In contrast, decreased IDE activity 
seems to be link with AD 
52
. The detected protective effect of IDE2 for AD could either result 
in a lower or in a higher IDE expression/activity prompting further investigations.  
The reported association of the downstream variant IDE7 with T2DM might be an indirect 
signal that extends from the IDE 3‟-UTR over LD (Manuscript I). T2DM is characterised as 
insulin resistance or insulin receptor insensitivities. Insulin resistance begins years before the 
onset of T2DM 
108
. Thus the presumed risk allele may attenuate translation or reduce the 
stability of the IDE mRNA, thus leading to less IDE activity and in a consequence less 
degrading of insulin, which can lead to a hyperinsulinemia and so explaining the increased 
T2DM susceptibility. Based on these assumptions, the presented study delineate the model 
that polymorphisms at opposing ends of the IDE gene lead to expression changes with 
consequences on susceptibility to different diseases: promoter variation increases IDE 
expression and protects from AD, while 3‟-UTR variation decreases IDE expression and 
increases T2DM risk. To concluded the polymorphisms of IDE seem to have opposing effects 
on IDE expression, a relevant endophenotype with disorder-specific effects on AD and T2DM 
susceptibility but not a common effect on both diseases. For more details see Manuscript I. 
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Common histopathological features of Alzheimer’s disease and type 2 diabetes mellitus 
Identifying potential common links between AD and T2DM makes it necessary not only to 
look on genetically influences of humans, it is also important to investigate directly human 
brain tissue for similar and different alterations in T2DM and AD. Because of the 
neurodegenerative decline in AD patients and also because of insulin is known to be 
synthesized in the brain as well as it is very important for cognition and memory 
109
 the brain 
should be in a special focus for the investigations of common links. For this issue the 
presented thesis analyzed 10 post-mortem brain tissues of four different groups: AD, AD 
combined with T2DM, T2DM and age-matched controls (see detailed methods Manuscript 
II). In all investigated patient groups significantly lower density of IRβ in the hippocampus 
region could be detected and additionally patient groups possessed significantly more 
PPARγ(p) positive cells than the control group in the investigated brain regions (Manuscript 
II). The particular study was focused especially on the phosphorylated form of PPARγ, which 
is the inactive variant of this protein 
110
 and which seems to play an important role in the 
pathophysiology of T2DM and maybe also in AD. PPARγ agonists improve insulin sensitivity 
by decreasing the level of circulating insulin, increasing insulin-mediated glucose uptake, and 
enhancing insulin action in the brain 
111
 . It was demonstrated that six months treatment with 
rosiglitazone, a typical T2DM treatment and a PPARγ agonist, preserved cognitive function 
for patients with AD and amnestic mild cognitive impairment compared with a placebo-
treated group 
83
. Several studies have examined potential mechanisms by which PPARγ 
agonists may ameliorate AD pathogenesis and progression (e.g. diminish proinflammatory 
gene expression and cytokine release 
112
, enhancing of antioxidant enzymes 
113
, improve to 
restore glucose uptake in the brain 
114
) and therefore it was not surprising to observe higher 
numbers of the inactive and not protective form PPARγ(p) positive cells in the brains of all 
patient groups compared to the control group. However, the presented study could not detect 
differences between the different patient groups (all groups were almost heavily affected, see 
results Manuscript II) suggesting that PPARγ(p) expression is equally enhanced in AD and 
T2DM and this fact seems to give a hint why PPARγ agonists having positive effects in AD 
patients as well as in T2DM patients.  
An interesting result of the study was that not only AD patients had a lower IRβ density in the 
brain, also the T2DM patient showed a lower density in the hippocampus. For AD it was 
already described that post-mortem cases of LOAD are associated with strikingly reduced 
levels of insulin, IGF-1 polypeptide, and related receptor genes in the whole brain 
75
 and so a 
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lower IRβ density in brain regions of AD patients fits into this circumstance. But it still does 
not solve the question, why should also T2DM patients have lower IRβ level in the 
hippocampus? T2DM is defined via insulin resistance, which is characterized by reduced 
responsiveness of IRs and decreased downstream signaling for the purpose of insulin 
stimulation. To compensate for these dysfunctions, the islet β-cells of the pancreas secrete 
more insulin, thereby creating a state of hyperinsulinemia another hallmark of T2DM 115. 
These facts are very well investigated in the periphery, but up to date no research group 
investigated the brains of T2DM patients with a special focus on IR density like in this study. 
For answering the question of lower IR density the insulin pathway and the link to the IR 
expression has to be further enlighten. As already mention in figure 3 (see Introduction) 
insulin activates the transmembrane IR leading to the activation of intracellular IRS. Active 
IRS leads to phosphorylation of PI3K, which activates AKT. Active AKT not only inhibits 
GSK3 it also inhibits forkhead box O (FOXO), which is a transcription factor that induces IR 
expression 116. In case of hyperinsulinemia, an overproduction of insulin exists in the body 
and so a negative feedback loop starts, which can lead to a lower density of IR (figure 5). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5: negative feedback loop of insulin and insulin receptor expression. Insulin activates the trans-
membrane insulin receptor (IR) leading to the activation of intracellular insulin receptor substrate (IRS). Active 
IRS leads to phosphorylation of phosphoinositide-3 kinase (PI3K), which activates protein kinase B (AKT). 
Once active, AKT leads to the phosphorylation and consequently to the inactivation transcription factor forkhead 
box O (FOXO). Inhibited FOXO leads to a lower or inhibited IR gene expression. → = activation;  •  = 
inhibition; x= inactive gene expression. 
 
Figure 5: negative 
feedback loop 
between insulin and 
insulin receptor 
expression 
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The presented result (Manuscripts II) can be explained via this negative feedback loop of 
insulin and IR. Unfortunately the study was unable to confirm the expectation that patients 
with AD plus T2DM had significantly fewer IRβ positive cells compared with the single 
disease groups. Thus, it seems that IRβ loss in the brain is a restricted phenomenon, and 
cannot decrease past a certain level. 
In conclusion, T2DM and AD may not be directly linked, but may share common histological 
features including lower numbers of IRβ positive cells in the hippocampus and higher 
numbers of PPARγ(p) positive cells in the prefrontal cortex and the hippocampus, which 
affirms that AD seems to be a type III diabetes. For more details see Manuscript II. 
 
Aggregation form of amyloid β42 influences gene/ protein expression 
Although more and more factors are found to be involved in AD as described in the previous 
chapters, excessive Aβ42 deposition is still considered to play a major role in AD. While post-
mortem studies are necessary for investigation of changes within the brain of AD patients, it 
is difficult to distinguish whether changes in gene-/protein expression were elicited directly 
by Aβ42 signaling or were a consequence of events taking place at later stage of the disease. 
Thus the presented thesis also used the neuroblastoma cell line SH-SY5Y (see detailed 
methods Manuscript III) to determine directly whether neurons exposed to Aβ42 peptides 
undergo pathological changes characteristic of AD brain and which influences do they have 
on genes and proteins involved in the insulin signaling pathway and in the APP pathway. 
Generally it is accepted that the oligomeric form of Aβ42 causes synapse dysfunction, 
including Tau hyperphosphorylation, calcium dysregulation and oxidative stress  blockade of 
fast axonal transport altered turnover of neuronal receptors involved in synaptic plasticity, and 
synapse loss, the molecular and cellular mechanisms underlying their toxicity are still poorly 
understood and need further clarification 117. The presented study investigated the effects of 
both soluble oligomeric and insoluble aggregated Aβ42 peptides on gene expression, protein 
level and enzyme activity in vitro to determine differences of the physical shape of the 
peptides. In particular, it was not possible to detect any significant influences of the different 
forms of Aβ42 peptides on IDE, IRS1, BACE, GSK3α or PI3K gene expression, but a strong 
influence of the soluble form of Aβ42 peptides on IR and GSK3β gene expression could be 
observed as well as on protein level (see results Manuscript III). Although it couldn’t be 
shown an influence of Aβ42 on GSK3α gene expression, the result of increased GSK3β 
gene/protein expression and also detected enhanced activity points to the fact, that GSK3β 
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might be a crucial element in the Aβ42-triggered molecular cascade leading to potential 
neurodegeneration. The GSK3β activity was implicated in tau phosphorylation, APP 
processing, Aβ42 production and neurodegeneration, which are all features of AD 48,118. 
Accordingly, over-expression of GSK3β in mice prevents the induction of long term 
potentiation (LTP) 119 and causes a decrease in spatial learning 120. Inhibitors of GSK3β have 
also been shown to block long-term depression (LTD) and GSK3β activity is enhanced during 
LTD 121. Thus, it would appear that GSK3β is critical for the induction of memory formation, 
switching off LTD and allowing LTP to occur. The observed effect of Aβ42 oligomers on 
GSK3β might be mediated by interaction with different receptors, but mainly with the 
interaction of IR. The signal transduction by neuronal IR is strikingly sensitive to disruption 
by soluble Aβ42 oligomers 122 and so the presented data indicate the fact that this relationship 
has the potential to generate an insidious pathogenic loop. It could be observed a significant 
reduction of IR gene and protein expression after SH-SY5Y treatment with soluble Aβ42 
oligomers compared to untreated cells. Consistent with the actual finding reported here, it 
could be already demonstrated that AD patients have less IR in hippocampus and in prefrontal 
cortex (see Manuscript II). Not only an impairment of IR leads to an activation of GSK3β as 
explained before, also OS can enhance the activity of this kinase 123. OS can result from the 
formation of H2O2 as a by-product of metabolism of aminergic neurotransmitters through 
MAO-B. It has been demonstrated that inhibitors of MAO-B, such as l-deprenyl and, more 
recently, rasagiline, are effective in the management of early symptoms of Parkinson's disease 
in the clinic and in animal models as well as in patients with mild AD 124. Furthermore ROS 
have been found in the vicinity of amyloid plaques 125 and increased MAO-B activity was 
found especially in platelets of AD patients 126. Therefore the presented results of enhanced 
MAO-B activity following treatment with aggregated while not with soluble Aβ42 peptides, 
might indicate the involvement of the fibrillar structures of Aβ42 in the OS cascade known to 
play an important role in AD 127,128. Anyhow the presented thesis is the first report indicating 
the direct influence of soluble or aggregated peptides on MAO-B activity in vitro and the 
presented data affirm that there has to be a direct neurobiochemical link between MAO-B and 
Aβ42. OS is not only involved in AD, it seems to contribute the development of microvascular 
and cardiovascular diseases in patients with T2DM 129, especially excessive ROS impair 
insulin synthesis and activate β-cell apoptotic signaling pathways. Additionally ROS may lead 
to inhibition of signaling at the level of IRS phosphorylation and insulin resistance 130. A 
recent study of Nunes and colleagues investigated the activity of MAO-B in T2DM patients 
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without finding any significant changes 131, which leads to the conclusion that OS is involved 
in the pathogenesis of T2DM but independent of MAO-B activity.  
In conclusion, our results suggest that Aβ42 oligomers seem to trigger more cellular 
mechanisms linked to AD than the insoluble aggregated Aβ42 peptides. 
 
OUTLOOK 
Based on current literature and the results presented in this thesis, there is an association 
between impaired cerebral insulin signaling pathway and AD, but it is still needs to be 
discerned whether it is a consequence, a result, or an epiphenomenon. Concerning of the 
existing investigation of IDE and the potentially protective effect on AD, a further step should 
be to analyze the influence of the SNPs on IDE enzyme activity within the brain. Sampling of 
post-mortem tissues of participant originating from the VITA cohort has already started, 
leading to an outstanding resource for AD research. Finding differences of IDE activity in AD 
patients compared to controls can help to develop potential new therapeutic targets, 
independent of BACE inhibition as main focus of the recent drug development. A further 
promising direction will be to study the direct influences of Aβ42 peptides on human neurons, 
especially of soluble peptides on insulin signaling pathways as well as synaptic 
genes/proteins, or those involved in neuronal survival. Taken into account that during the past 
100 years of research in AD neither an effective causative therapy nor preventative strategy 
has been developed, understanding of etiology and molecular pathogenesis of AD appears as 
natural prerequisite for this. Considering the increased incidence of AD in the next few 
decades, investigating molecular pathogenesis as a basis for developing cure and prevention 
of AD will be one of the main medical challenges of our century. 
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